

CITATION REPORT

List of articles citing

New type of cardiomyopathy associated with diabetic glomer

DOI: 10.1016/0002-9149(72)90595-4
American Journal of Cardiology, 1972, 30, 595-602.

Source: <https://exaly.com/paper-pdf/10964443/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1369	Diabetic Cardiomyopathy. 1974 , 229, 1749		249
1368	Role of diabetes in congestive heart failure: the Framingham study. <i>American Journal of Cardiology</i> , 1974 , 34, 29-34	3	1495
1367	Diabetes and the heart. 1975 , 90, 283-9		22
1366	Left ventricular function in diabetes mellitus. 1975 , 90, 537		
1365	Neuropathic and vascular complications occurring in diabetes. 1976 , 59, 169-74		3
1364	Exercise testing in young asymptomatic diabetic patients. 1976 , 27, 539-48		22
1363	Cardiomyopathic syndrome due to coronary arter disease. II: Increased prevalence in patients with diabetes mellitus: a matched pair analysis. 1977 , 39, 740-7		35
1362	Pathogenesis of diabetic microangiopathy. 1977 , 1, 1555-6		6
1361	Diabetic cardiomyopathy: the preclinical phase. 1977 , 1, 1444-6		94
1360	The heart in diabetes: autonomic neuropathy and cardiomyopathy. 1977 , 6, 377-88		77
1359	Diabetes and the heart: coronary heart disease. 1977 , 6, 389-402		25
1358	Diabetes prevalence in patients with bradycardiac arrhythmias. 1977 , 14, 229-34		18
1357	Some histochemical observations on the myocardial metabolism in experimental conditions. Part I. 1978 , 61, 257-72		3
1356	Noninvasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. 1978 , 27, 127-34		71
1355	Asymptomatic coronary artery disease: angiographic assessment of diabetics evaluated for renal transplantation. 1978 , 58, 1184-90		70
1354	Diabetic cardiomyopathy? An echocardiographic study of young diabetics. 1978 , 1, 404-7		111
1353	Effect of diabetes therapy on the myocardium in experimental diabetes. 1979 , 16, 129-38		37

1352	Myocardial dysfunction without coronary artery disease in diabetic renal failure. <i>American Journal of Cardiology</i> , 1979 , 43, 193-9	3	68
1351	Diabetes and Cardiovascular Disease. 1979 , 241, 2035		2245
1350	Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. 1979 , 2, 120-6		963
1349	Intramyocardial microarteriopathy. 1980 , 388, 289-311		22
1348	Cardiovascular disease in patients on chronic hemodialytic therapy. 1980 , 22, 343-56		38
1347	Lysosomal enzymes in experimental diabetic cardiomyopathy. 1980 , 13, 227-31		8
1346	Prospective study of heart disease in untreated maturity onset diabetics. 1980 , 44, 342-8		57
1345	The effect of diabetes on performance and metabolism of rat hearts. 1980 , 47, 911-21		237
1344	Collagen metabolism in the myocardium from streptozotocin-diabetic rats. 1980 , 29, 547-50		26
1343	Cardiomyopathy in Diabetes Mellitus. 1980 , 31, 502-4		5
1342	Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. 1980 , 99, 446-58		204
1341	Absence of correlation between coronary arterial atherosclerosis and severity or duration of diabetes mellitus of adult onset. <i>American Journal of Cardiology</i> , 1980 , 46, 535-42	3	87
1340	The effect of streptozotocin-induced diabetes in rats on cardiac contractile proteins. 1981 , 49, 1243-50		205
1339	Exercise testing with myocardial scintigraphy in asymptomatic diabetic males. 1981 , 63, 54-64		86
1338	Left ventricular function in diabetes mellitus. I: Methodology, and prevalence and spectrum of abnormalities. 1981 , 45, 122-8		95
1337	Left ventricular function in diabetes mellitus. II: Relation between clinical features and left ventricular function. 1981 , 45, 129-32		96
1336	Comparative study of the echocardiographic findings in hypertensive and nonhypertensive cardiomyopathy. 1982 , 33, 17-32		
1335	Specific heart disease in diabetes mellitus. 1982 , 284, 140-1		28

- 1334 [Diabetic cardiomyopathy: clinical, hemodynamic and histopathologic aspects. Case report]. **1982**, 3, 197-204 1
- 1333 Diabetes and the heart. *American Journal of Cardiology*, **1982**, 49, 2043-4 3
- 1332 Coronary artery disease in diabetic and nondiabetic patients: a clinical and angiographic comparison. **1983**, 6, 440-6 27
- 1331 Preclinical abnormality of left ventricular performance in patients with insulin-dependent diabetes mellitus. **1983**, 20, 311-20 15
- 1330 Hypertensive diabetic cardiomyopathy in the rat: ultrastructural features. **1983**, 398, 305-17 32
- 1329 Clinical trials of an antiplatelet agent, ticlopidine, in diabetes mellitus. **1983**, 8, 518-23 4
- 1328 Diabetic cardiomyopathy in rats: mechanical and biochemical response to different insulin doses. **1984**, 247, H817-23 12
- 1327 Reduced transc coronary exchange and prostaglandin synthesis in diabetic rat heart. **1984**, 247, H563-9 11
- 1326 Combined renovascular hypertension and diabetes in rats: a new preparation of congestive cardiomyopathy. **1984**, 70, 318-30 61
- 1325 Abnormalities of the Cardiovascular Response to Cold Pressor Test in Type 1 Diabetes. **1984**, 144, 43 14
- 1324 Ultrastructure of heart muscle in short-term diabetic rats: influence of insulin treatment. **1984**, 27, 397-402 21
- 1323 Diabetic myocardial alterations in ultrastructure and function. **1984**, 25, 215-21 12
- 1322 Effect of experimental infarct on the mortality rate in alloxan-diabetic rats. **1984**, 25, 81-4 1
- 1321 Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. **1984**, 37, 407-15 103
- 1320 A Prospective Study of Heart Disease in Diabetes Mellitus. **1984**,
- 1319 Juvenile diabetes and the heart. **1984**, 31, 653-63 3
- 1318 Diabetic cardiomyopathy: the available evidence. **1985**, 30, 83-8 1
- 1317 Diabetic cardiomyopathy. **1985**, 27, 255-70 246

1316	Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. 1985 , 1, 43-7	85
1315	Insulin-dependent diabetes mellitus and ischemic heart disease. 1985 , 8 Suppl 1, 65-70	36
1314	[Existence of asymptomatic changes in left ventricular function in the diabetic. Noninvasive study]. 1985 , 6, 68-76	4
1313	Defective energy metabolism of the heart in diabetes. 1985 , 1, 139-41	46
1312	Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. 1985 , 110, 1100-7	508
1311	Abnormal cardiovascular response to exercise in young asymptomatic diabetic patients with retinopathy. 1986 , 112, 554-60	36
1310	Reversibility of diabetic cardiomyopathy with insulin in rabbits. 1986 , 250, H108-13	5
1309	Cardiac function and coronary arteriography in asymptomatic type 1 (insulin-dependent) diabetic patients: evidence for a specific diabetic heart disease. 1986 , 29, 706-12	70
1308	Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy. 1986 , 9, 375-82	43
1307	Myocardial performance and metabolism in non-ketotic, diabetic rat hearts: myocardial function and metabolism in vivo and in the isolated perfused heart under the influence of insulin and octanoate. 1986 , 81, 620-35	32
1306	Impaired cardiac adjustment to pregnancy in type I diabetes. 1986 , 9, 376-83	29
1305	Metabolic and morphological changes of the heart in Chinese hamsters (CHAD strain) with spontaneous long-term diabetes. 1987 , 3, 297-305	16
1304	Atherosclerosis risk factors. 1987 , 32, 207-35	27
1303	Alterations in heart and serum lysosomal activities in streptozotocin-induced diabetes. 1987 , 82, 271-8	6
1302	Sulfate metabolism in the alloxan-diabetic rat: relationship of altered sulfate pools to proteoglycan sulfation in heart and other tissues. 1987 , 30, 259-67	18
1301	Ultrastructural alterations in cardiac muscle of diabetic BB Wistar rats. 1987 , 411, 45-52	29
1300	Influence of acute hyperglycemia on left ventricular function in diabetics assessed by echocardiography. 1987 , 10, 594-7	2
1299	Structural manifestations of diabetic cardiomyopathy in the rat and its reversal by insulin treatment. 1988 , 182, 270-82	58

1298	Left ventricular relaxation and filling pattern in diabetic heart muscle disease: an echocardiographic study. 1988 , 66, 773-8		9
1297	Impairment of diastolic function in middle-aged type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients free of cardiovascular disease. 1988 , 31, 783-91		58
1296	Diabetic cardiopathy: is it a real entity?. 1988 , 4, 273-88		26
1295	Left ventricular filling determined by Doppler echocardiography in diabetes mellitus. <i>American Journal of Cardiology</i> , 1988 , 61, 1140-3	3	51
1294	Mitochondrial creatine phosphokinase deficiency in diabetic rat heart. 1988 , 154, 469-75		32
1293	Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. 1988 , 12, 114-20		203
1292	Cardiomyopathy in childhood diabetes mellitus: incidence, time of onset, and relation to metabolic control. 1988 , 19, 225-36		29
1291	Asymptomatic diabetic cardiomyopathy: a noninvasive study. 1988 , 4, 183-90		36
1290	Beneficial effects of verapamil in diabetic cardiomyopathy. 1988 , 37, 936-42		87
1289	Effects of Beta-Adrenoceptor Blocking Agents on Isolated Atrial and Papillary Muscles from Experimentally Diabetic Rats. 1989 , 49, 67-76		1
1288	Exercise testing, clinical, and angiographic characteristics of anginal patients with and without diabetes mellitus. 1989 , 40, 656-65		4
1287	Diabetic heart disease--Part II: The clinical and pathological spectrum. 1989 , 12, 667-71		6
1286	Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. <i>American Journal of Cardiology</i> , 1989 , 64, 1010-6	3	100
1285	Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. 1989 , 14, 593-602		45
1284	Diabetic cardiomyopathy. 1989 , 118, 1000-12		203
1283	Myocardial disease in hypertensive-diabetic patients. 1989 , 87, 235-285		23
1282	Effects of beta-adrenoceptor blocking agents on isolated atrial and papillary muscles from experimentally diabetic rats. 1989 , 49, 67-76		5
1281	Non-invasive evaluation of cardiac function in young patients with type 1 diabetes. 1989 , 6, 677-81		14

1280	Evidence for a specific heart disease of diabetes in humans. 1990 , 7, 478-89	23
1279	Effects of anoxia and low free fatty acid on myocardial energy metabolism in streptozotocin-diabetic rats. 1990 , 34, 259-65	17
1278	A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. 1990 , 82, 848-55	271
1277	Abnormal diastolic function in patients with type 1 diabetes and early nephropathy. 1990 , 64, 266-71	24
1276	Diabetic heart muscle disease. 1990 , 22, 377-86	62
1275	Endomyocardial biopsy diagnosis of small vessel disease: a clinicopathologic study. 1990 , 26, 103-10	31
1274	Altered functional activity and anoxic tolerance in diabetic rat isolated atria. 1990 , 279, 183-7	9
1273	Correlation between histopathological changes and mechanical dysfunction in diabetic rat hearts. 1991 , 11, 177-88	21
1272	Beneficial effects of diltiazem on the natural history of hypertensive diabetic cardiomyopathy in rats. 1991 , 18, 1406-17	18
1271	Diabetes and arterial disease. 1991 , 8 Spec No, S82-7	11
1270	Cardiac function and exercise capacity of diabetic patients. 1991 , 37 Suppl, S25-33	
1269	Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. 1992 , 20, 736-44	232
1268	Ultrasound tissue characterization of the diabetic heart: laboratory curiosity or clinical tool?. 1992 , 19, 1163-4	6
1267	Scintigraphic evaluation of left ventricular function and correlation with autonomic cardiac neuropathy in diabetic patients. 1992 , 81, 14-24	8
1266	Anatomical and functional cardiac abnormalities in type I diabetes. 1992 , 70, 403-10	9
1265	Radionuclide assessment of left ventricular function in patients with myocardial infarction and diabetes mellitus. 1992 , 231, 73-6	7
1264	Increased rat myocardial type VI collagen in diabetes mellitus and hypertension. 1993 , 36, 93-8	47
1263	Increased capillary permeability to albumin in diabetic rat myocardium. 1993 , 72, 947-57	39

1262	Collagen remodelling in myocardia of patients with diabetes. 1993 , 46, 32-6		160
1261	Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. 1993 , 42, 1017-25		345
1260	Left ventricular diastolic filling properties in diabetic patients during isometric exercise. 1993 , 83, 316-23		23
1259	The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings. 1993 , 6, 989-95		30
1258	Role of glucose intolerance in cardiac diastolic function in essential hypertension. 1994 , 23, 1002-5		30
1257	Cardiovascular status in young patients with insulin-dependent diabetes mellitus. 1994 , 90, 357-61		44
1256	Diabetic cardiomyopathy. 1994 , 8, 65-73		103
1255	Left ventricular systolic function in middle-aged patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 1994 , 73, 1202-8	3	39
1254	L-arginine reduces heart collagen accumulation in the diabetic db/db mouse. 1994 , 90, 479-83		46
1253	Preservation of Left Ventricular function and Coronary Flow by Angiotensin I-Converting Enzyme Inhibition in the Hypertensive-Diabetic Dahl Rat. 1994 , 7, 919-925		14
1252	Glucose intolerance exaggerates left ventricular hypertrophy and dysfunction in essential hypertension. 1994 , 7, 1110-4		25
1251	Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. <i>American Journal of Cardiology</i> , 1995 , 76, 1173-6	3	107
1250	Diastolic dysfunction is not related to changes in glycaemic control over 6 months in type 2 (non-insulin-dependent) diabetes mellitus. A cross-sectional study. 1995 , 32, 110-5		25
1249	Effect of high glucose on formation of extracellular matrix components by cultured rat heart endothelial cells. 1995 , 38, 430-6		25
1248	Diabetic cardiomyopathy: the significance of creatine. 1995 , 45, 41-4		2
1247	Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. 1995 , 25, 1408-15		97
1246	Heart disease in diabetes mellitus. 1996 , 25, 425-38		29
1245	Myocardial alterations in diabetes and hypertension. 1996 , 31 Suppl, S133-42		30

1244	Diabetic and hypertensive heart disease. 1996 , 125, 304-10		116
1243	Mitochondrial respiratory impairment in streptozotocin-induced diabetic rat heart. 1996 , 60, 673-82		49
1242	Left ventricular performance and autonomic dysfunction in patients with long-term insulin-dependent diabetes mellitus. 1996 , 33, 269-73		11
1241	Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. 1996 , 160-161, 283-8		56
1240	Regulation of energy substrate metabolism in the diabetic heart. 1997 , 34, 25-33		351
1239	Prolonged ejection duration helps to maintain pump performance of the renal-hypertensive-diabetic rat heart: correlations between isolated papillary muscle function and ventricular performance in situ. 1997 , 34, 230-40		11
1238	Exercise responses in patients with IDDM. 1997 , 20, 1814-21		35
1237	Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. 1997 , 46 Suppl 2, S119-24		65
1236	Myocardial mechanics and titin in experimental insulin-resistant rats. 1997 , 38, 717-28		11
1235	Echocardiographic Changes in Cases of Intermittent Acute Porphyria. 1997 , 14, 223-230		
1234	Myocardial blood flow and glucose metabolism in diabetes mellitus. <i>American Journal of Cardiology</i> , 1997 , 80, 94A-101A	3	42
1233	A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. 1997 , 12, 267-74		92
1232	Diabetic cardiomyopathy. 1998 , 21, 885-7		100
1231	123I-MIBG myocardial scintigraphy in diabetic patients: relationship with 201Tl uptake and cardiac autonomic function. 1998 , 12, 323-31		20
1230	[Heart pathology of extracardiac origin. XI. Cardiac repercussions of diabetes mellitus]. 1998 , 51, 661-70		7
1229	Mechanism of impaired left ventricular wall motion in the diabetic heart without coronary artery disease. 1998 , 21, 2123-8		17
1228	Use of iodine-123 metaiodobenzylguanidine scintigraphy to assess cardiac sympathetic denervation and the impact of hypertension in patients with non-insulin-dependent diabetes mellitus. 1999 , 26, 1310-6		12
1227	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. 1999 , 100, 1134-46		1470

1226	Maternally transmitted susceptibility to non-insulin-dependent diabetes mellitus and left ventricular hypertrophy. 1999 , 33, 1372-8		9
1225	Altered creatine kinase enzyme kinetics in diabetic cardiomyopathy. A(31)P NMR magnetization transfer study of the intact beating rat heart. 1999 , 31, 2175-89		36
1224	Diabetes and the heart. 1999 , 60, 90-4		
1223	Impaired glucose tolerance as a determinant of early deterioration of left ventricular diastolic function in middle-aged healthy subjects. <i>American Journal of Cardiology</i> , 2000 , 85, 790-2, A9	3	12
1222	Prognosis of aortic intramural hemorrhage compared with classic aortic dissection. <i>American Journal of Cardiology</i> , 2000 , 85, 792-5, A10	3	98
1221	Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus?. 2000 , 7, 562-8		15
1220	Dilated cardiomyopathy as the first early complication in a 14 year-old girl with diabetes mellitus type 1. 2000 , 13, 1143-6		4
1219	Effects of acute hyperglycaemia on cardiac function: an echocardiographic study of monozygotic twins. 2000 , 74, 139-44		3
1218	Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. 2000 , 13, 1149-54		35
1217	The effects of chronic L-name and L-arginine administration on beta-adrenergic responsiveness of STZ-diabetic rat atria. 2000 , 41, 565-70		6
1216	[Cardiomyopathy in diabetes mellitus]. 2000 , 115, 27-35		1
1215	[Left ventricular diastolic dysfunction in young people with type 1 diabetes mellitus. Associated factors]. 2000 , 53, 603-10		0
1214	Cardiomyopathy and heart failure in diabetes. 2001 , 30, 1031-46		16
1213	Ryanodine receptor dysfunction in hearts of streptozotocin-induced diabetic rats. 2001 , 60, 1356-64		45
1212	Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. 2001 , 281, H1137-47		98
1211	Serum HbA1c levels and exercise capacity in diabetic patients. 2001 , 42, 607-16		22
1210	Oxidative stress and diabetic cardiomyopathy: a brief review. 2001 , 1, 181-93		278
1209	Left ventricular function in Nigerian Africans with non-insulin-dependent diabetes mellitus. <i>American Journal of Cardiology</i> , 2001 , 87, 1026-9; A6	3	3

1208	Diabetes. 2001 , 59, 159-72	4
1207	Diabetic cardiomyopathy: fact or fiction?. 2001 , 85, 247-8	83
1206	Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. 2002 , 51, 1938-48	520
1205	Overexpression of metallothionein reduces diabetic cardiomyopathy. 2002 , 51, 174-81	159
1204	Regulatory networks controlling mitochondrial energy production in the developing, hypertrophied, and diabetic heart. 2002 , 67, 371-82	15
1203	Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. 2002 , 283, H1398-408	199
1202	Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. 2002 , 34, 1249-57	122
1201	Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. 2002 , 98, 33-9	214
1200	Peroxisome Proliferator-activated Receptor (PPAR) Signaling in the Gene Regulatory Control of Energy Metabolism in the Normal and Diseased Heart. 2002 , 34, 1249-1257	107
1199	Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. 2002 , 359, 1430-2	119
1198	Experimental diabetes and left ventricular hypertrophy: effects of beta-receptor blockade. 2002 , 11, 229-37	37
1197	[Prevention and treatment of congestive heart failure in diabetic patients]. 2002 , 55, 1083-7	3
1196	. 2002 ,	10
1195	Cardiac Complications and Management. 577-605	
1194	Angiotensin-Converting Enzyme Inhibitor Ramipril Improves Coronary Microvascular Remodeling in Type II Diabetic Rats. 2002 , 32, 680	
1193	Diagnosing coronary artery disease in diabetic patients. 2002 , 18, 201-8	12
1192	Left ventricular diastolic function is related to glucose in a middle-aged population. 2002 , 251, 415-20	30
1191	Non-invasive magnetic resonance imaging assessment of myocardial changes and the effects of angiotensin-converting enzyme inhibition in diabetic rats. 2002 , 538, 541-53	31

1190	Magnetic resonance imaging analysis of cardiac cycle events in diabetic rats: the effect of angiotensin-converting enzyme inhibition. 2002 , 538, 555-72	32
1189	Diabetic heart dysfunction: is cell transplantation a potential therapy?. 2003 , 8, 213-9	12
1188	Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. 2003 , 249, 113-123	24
1187	Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. 2003 , 19, 487-93	36
1186	Influence of diabetes mellitus on heart failure risk and outcome. 2003 , 2, 1	125
1185	Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats. 2003 , 48, 429-35	53
1184	Mitochondria respiration and susceptibility to ischemia-reperfusion injury in diabetic hearts. 2003 , 420, 298-304	13
1183	A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. 2003 , 100, 1226-31	438
1182	Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. 2003 , 29, 6S53-61	26
1181	Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?. 2003 , 29, 455-66	87
1180	Atherosclerosis, Hypertension and Diabetes. 2003 ,	2
1179	Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. 2003 , 26, 2791-5	163
1178	Diabetic cardiomyopathy. 2003 , 26, 2949-51	159
1177	Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes. 2003 , 5, 189-99	2
1176	Streptozotocin-induced diabetes increases disulfide bond formation on cardiac ryanodine receptor (RyR2). 2003 , 305, 989-98	44
1175	Cardiovascular disease and diabetes. 2003 , 26, 230-7	23
1174	Diabetes mellitus and heart failure. 2003 , 1, 273-80	11
1173	Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. 2003 , 52, 1825-36	107

1172	Mechanisms in the pathogenesis of diabetic cardiomyopathy. 2003 , 10, 251-255	4
1171	Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. 2003 , 105, 591-9	149
1170	Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca ²⁺ -ATPase. 2004 , 53, 463-73	181
1169	Effects of halothane on contraction and intracellular calcium in ventricular myocytes from streptozotocin-induced diabetic rats. 2004 , 92, 246-53	9
1168	Nuclear receptor signaling and cardiac energetics. 2004 , 95, 568-78	363
1167	Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. 2004 , 279, 48085-90	39
1166	Long-term, cause-specific mortality after myocardial infarction in diabetes. 2004 , 25, 926-31	32
1165	Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. 2004 , 287, E896-905	212
1164	Regeneration of the heart in diabetes by selective copper chelation. 2004 , 53, 2501-8	121
1163	Left ventricular dysfunction in normotensive Type 1 diabetic patients: the impact of autonomic neuropathy. 2004 , 21, 524-30	43
1162	Left bundle branch block in type 2 diabetes mellitus: a sign of advanced cardiovascular involvement. 2004 , 9, 362-5	11
1161	Diabetes decreases mRNA levels of calcium-release channels in human atrial appendage. 2004 , 263, 143-50	15
1160	Some considerations about the composition, in vivo detection and therapeutic approaches to the coronary atherosclerotic plaques in diabetes mellitus. 2004 , 18, 51-3	
1159	The ABC transporter structure and mechanism: perspectives on recent research. 2004 , 61, 682-99	406
1158	Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. 2004 , 22, 553-68	37
1157	Preventing heart failure in patients with diabetes. 2004 , 88, 1237-56	10
1156	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. 2004 , 107, 539-57	250
1155	Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. 2004 , 94, 47-51	31

1154	Usefulness of B-type natriuretic peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus. 2004 , 30, 381-6		9
1153	Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. 2004 , 25, 543-67		711
1152	Effect of training on beta1 beta2 beta3 adrenergic and M2 muscarinic receptors in rat heart. 2004 , 36, 949-54		36
1151	Altered exercise gas exchange as related to microalbuminuria in type 2 diabetic patients. 2004 , 125, 1292-8		20
1150	Imaging of myocardial metabolism. 2005 , 12, 345-58		22
1149	Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. 2005 , 26, 908-17		141
1148	Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. 2005 , 5, 285-92		41
1147	Overexpression of hexokinase protects hypoxic and diabetic cardiomyocytes by increasing ATP generation. 2005 , 5, 293-300		18
1146	Left ventricular function in patients with type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2005 , 95, 798-801	3	9
1145	Changes in crossbridge mechanical properties in diabetic rat cardiomyopathy. 2005 , 100, 231-9		12
1144	Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression. 2005 , 19, 105-12		37
1143	Relation between Serum Carboxy-Terminal Propeptide of Type 1 Procollagen(PIP), a Marker of Myocardial Fibrosis, and Left Ventricular Diastolic Function in Patients with Early Type 2 Diabetes Mellitus. 2005 , 35, 500		4
1142	[Diastolic dysfunction in diabetic normotensive patients, regardless of the presence of microangiopathy]. 2005 , 84, 461-6		3
1141	Frequent non-cardiac comorbidities in patients with chronic heart failure. 2005 , 7, 309-16		71
1140	The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. 2005 , 54, 204-11		62
1139	Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. 2005 , 111, 2073-85		263
1138	Partial reversal by rutin and quercetin of impaired cardiac function in streptozotocin-induced diabetic rats. 2005 , 83, 343-55		40
1137	Effects of diabetes on ryanodine receptor Ca release channel (RyR2) and Ca ²⁺ homeostasis in rat heart. 2005 , 54, 3082-8		135

1136	Molecular defects in cardiac myofibrillar proteins due to thyroid hormone imbalance and diabetes. 2005 , 83, 1071-91	24
1135	Differences in the immediate effects of smoking on left ventricular diastolic function between healthy volunteers and patients with type 2 diabetes mellitus. 2005 , 18, 320-5	5
1134	Therapy insight: heart disease and the insulin-resistant patient. 2005 , 2, 252-60	9
1133	Genetic modification of the heart: transgenic modification of cardiac lipid and carbohydrate utilization. 2005 , 39, 581-93	17
1132	Heart Failure and Cardiac Dysfunction in Diabetes. 2005 , 555-578	
1131	Diabetes Mellitus and Heart Disease. 2005 , 579-628	
1130	Diabetes and Cardiovascular Disease. 2005 ,	6
1129	Diabetic dyslipidemia and the heart. 2006 , 2, 37-52	1
1128	Diabetic cardiomyopathy: where are we 40 years later?. 2006 , 22, 305-8	26
1127	Identifying which patients with diabetes should be tested for the presence of coronary artery disease--the importance of baseline electrocardiogram and exercise testing. 2006 , 22 Suppl A, 9A-15A	9
1126	Diabetic cardiomyopathy. 2006 , 35, 575-99, ix	45
1125	[Diabetic miocardiopathy]. 2006 , 127, 584-94	7
1124	Diabetic cardiomyopathy. 2006 , 2, 71-80	2
1123	Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. 2006 , 47, 384-90	95
1122	The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. 2006 , 47, 693-700	343
1121	Cardiac cell death in early diabetes and its modulation by dietary fatty acids. 2006 , 1761, 1148-62	35
1120	Oxidative stress in diabetes: a mechanistic overview of its effects on atherogenesis and myocardial dysfunction. 2006 , 38, 794-803	124
1119	Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes. 2006 , 110, 206-11	46

1118	Causes and characteristics of diabetic cardiomyopathy. 2006 , 3, 108-17		89
1117	Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. 2006 , 21, 250-8		134
1116	Hyperglycemia and nocturnal systolic blood pressure are associated with left ventricular hypertrophy and diastolic dysfunction in hypertensive diabetic patients. 2006 , 5, 19		16
1115	Heart specific up-regulation of genes for B-type and C-type natriuretic peptide receptors in diabetic mice. 2006 , 36, 69-75		20
1114	Identification of diabetic cardiomyopathy with cardiac magnetic resonance imaging. 2006 , 22, 91-2		1
1113	The diabetic myocardium. 2006 , 6, 36-41		9
1112	Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. 2006 , 1, 326-33		24
1111	Evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. <i>American Journal of Cardiology</i> , 2006 , 98, 1525-30	3	32
1110	Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. 2006 , 111, 384-99		75
1109	Impaired myocardial function in newly onset type 2 diabetes associates with arterial stiffness. 2006 , 7, 341-7		16
1108	Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. 2006 , 55, 798-805		302
1107	Review: Heart failure complicating acute myocardial infarction in patients with diabetes: pathophysiology and management strategies. 2006 , 6, 191-196		
1106	Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. 2006 , 1, 193-208		44
1105	Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. 2006 , 113, 1235-43		147
1104	Asymptomatic cardiomyopathy in children and adolescents with type 1 diabetes mellitus: association of echocardiographic indicators with duration of diabetes mellitus and metabolic parameters. 2006 , 19, 713-26		11
1103	Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. 2007 , 292, H2106-18		67
1102	Angiotensin II and the cardiac complications of diabetes mellitus. 2007 , 13, 2721-9		18
1101	Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. 2007 , 28, 2465-71		58

1100	Diabetes and the endocrine heart. 2007 , 28, 2427-9	6
1099	Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. 2007 , 8, 480-6	24
1098	Non-invasive diagnostic imaging techniques as a window into the diabetic heart: a review of experimental and clinical data. 2007 , 115, 211-20	11
1097	CD36 deficiency rescues lipotoxic cardiomyopathy. 2007 , 100, 1208-17	192
1096	Endocrine Disorders and the Heart. 2007 , 2295-2330	1
1095	Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. 2007 , 115, 909-17	180
1094	Transcriptomic analysis of the cardiac left ventricle in a rodent model of diabetic cardiomyopathy: molecular snapshot of a severe myocardial disease. 2007 , 28, 284-93	22
1093	Differential impact of left ventricular mass and relative wall thickness on cardiovascular prognosis in diabetic and nondiabetic hypertensive subjects. 2007 , 154, 79.e9-15	25
1092	Early diabetic heart disease: just another manifestation of vasculopathy?. 2007 , 20, 556-7	
1091	Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione. 2007 , 13, 884-92	31
1090	The PPAR regulatory system in cardiac physiology and disease. 2007 , 73, 269-77	142
1089	Calcium Signalling and Disease. 2007 ,	20
1088	Diabetic cardiomyopathy revisited. 2007 , 115, 3213-23	1161
1087	Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. 2007 , 9, 911-29	77
1086	[Diabetic cardiomyopathy]. 2007 , 51, 160-7	10
1085	Left ventricle diastolic dysfunction in diabetes: an update. 2007 , 51, 168-75	14
1084	Investigation of diabetes-induced effect on apex of rat heart myocardium by using cluster analysis and neural network approach: An FTIR study. 2007 , 21, 269-278	5
1083	Restoration of diabetes-induced abnormal local Ca ²⁺ release in cardiomyocytes by angiotensin II receptor blockade. 2007 , 292, H912-20	52

1082	. 2007,	13
1081	Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). 2007, 6, 6	45
1080	Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. 2007, 5, 32	34
1079	Disturbed glucose metabolism is associated with left ventricular dysfunction using tissue Doppler imaging in patients with myocardial infarction. 2007, 27, 60-6	4
1078	Role of exercise and metabolism in heart failure with normal ejection fraction. 2007, 49, 263-74	10
1077	Diabetic cardiomyopathy. 2007, 9, 467-73	28
1076	Sarcoplasmic Ca ²⁺ release is prolonged in nonfailing myocardium of diabetic patients. 2008, 308, 141-9	25
1075	[Diabetic cardiomyopathy--a type of coronary artery disease?]. 2008, 49, 436-40	5
1074	The complexities of diabetic cardiomyopathy: lessons from patients and animal models. 2008, 8, 243-8	25
1073	Cardiovascular impairment in children, adolescents, and young adults with type 1 diabetes mellitus (T1DM). 2008, 167, 877-84	20
1072	Intracardiac lipid accumulation, lipotrophy of muscle cells and expansion of myocardial infarction in type 2 diabetic patients. 2008, 39, 944-51	19
1071	Diabetic cardiomyopathy: how much does it depend on AGE?. 2008, 154, 725-6	20
1070	Protective action of doxycycline against diabetic cardiomyopathy in rats. 2008, 155, 1174-84	52
1069	Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). <i>American Journal of Cardiology</i> , 2008, 101, 634-8	3 103
1068	Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. 2008, 22, 137-43	14
1067	Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. 2008, 5, 715-24	76
1066	Steatosis and diastolic dysfunction: the skinny on myocardial fat. 2008, 52, 1800-2	7
1065	Diastolic Heart Failure. 2008,	3

1064	Uncomplicated diabetes mellitus is equivalent for coronary artery disease: new support from novel angiographic myocardial perfusion-myocardial blush. 2008 , 127, 262-5	12
1063	Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. 2008 , 121, 748-57	356
1062	Diabetes-related metabolic perturbations in cardiac myocyte. 2008 , 34 Suppl 1, S3-9	34
1061	Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus. 2008 , 6, 109-25	9
1060	Diabetic heart disease. 2006 , 92, 296-300	52
1059	Diabetes Mellitus. 2008 , 333-342	
1058	Left ventricular diastolic function in normotensive type-2 diabetic subjects. 2008 , 100, 1066-72	5
1057	Using Myocardial Imaging to Identify and Manage Subclinical Heart Disease in Diabetes Mellitus and Obesity. 2008 , 185-197	
1056	Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. 2008 , 294, E1109-18	50
1055	Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. 2008 , 295, R1439-45	46
1054	Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. 2008 , 117, 43-51	509
1053	The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium. 2008 , 2008, 253817	46
1052	O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function. 2008 , 103, 1354-8	103
1051	Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. 2008 , 57, 2158-66	43
1050	Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. 2008 , 114, 195-210	145
1049	Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. 2008 , 114, 313-20	43
1048	Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. 2008 , 33, 459-72	28
1047	Cardiac metabolism in diabetes mellitus. 2008 , 14, 2521-6	13

1046	Optimization of cardiac metabolism in diabetes mellitus. 2008 , 14, 2537-50	8
1045	Mitochondrial Dysfunction in Diabetic Cardiomyopathy. 2008 , 32, 467	
1044	[Link between diabetes and diastolic dysfunction and the diagnostic role of echocardiography]. 2009 , 150, 2060-7	
1043	Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. 2009 , 4, e6474	26
1042	Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. 2009 , 297, H829-35	37
1041	The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation. 2009 , 23, 709-17	10
1040	The dialogue between diabetes and diastole. 2009 , 11, 3-5	7
1039	Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. 2009 , 23, 2176-85	27
1038	Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. 2009 , 23, 273-82	27
1037	Effect of correction of hyperglycemia on left ventricular function in non-insulin-dependent (type 2) diabetics. 1983 , 213, 363-8	49
1036	Impaired left ventricular filling in young female diabetics. An echocardiographic study. 1984 , 216, 509-16	49
1035	Left ventricular function in newly diagnosed non-insulin-dependent (type 2) diabetics evaluated by systolic time intervals and echocardiography. 1985 , 217, 379-88	26
1034	REFERENCES. 2009 , 222, 58-69	
1033	Left ventricular geometric patterns in normotensive type 2 diabetic patients in Nigeria: an echocardiographic study. 2009 , 12, 184-8	3
1032	DIABETIC CARDIOPATHY.. 2009 , 84A, 421-428	2
1031	[Heart failure in diabetes]. 2009 , 159, 134-40	0
1030	Antioxidants but not doxycycline treatments restore depressed beta-adrenergic responses of the heart in diabetic rats. 2009 , 9, 21-9	16
1029	The failing diabetic heart: focus on diastolic left ventricular dysfunction. 2009 , 9, 79-86	32

1028	Seek and destroy: the ubiquitin-proteasome system in cardiac disease. 2009 , 11, 396-405	17
1027	Current status of cardiac MR spectroscopy. 2009 , 54, 255-277	5
1026	Diabetische Herzinsuffizienz. 2009 , 3, 20-24	
1025	Influence of cardiovascular autonomic neuropathy on atherogenesis and heart function in patients with type 1 diabetes. 2009 , 83, 26-31	9
1024	Type 2 diabetes, mitochondrial biology and the heart. 2009 , 46, 842-9	40
1023	Diabetic cardiomyopathy--a distinct disease?. 2009 , 23, 347-60	53
1022	Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. 2009 , 18, 11-8	37
1021	Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity. 2009 , 58, 682-8	2
1020	Rodent models of diabetic cardiomyopathy. 2009 , 2, 454-66	202
1019	Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. 2009 , 41, 977-84	62
1018	Diabetic cardiomyopathy. 2009 , 116, 741-60	123
1017	Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease (Supplementary Material). 2010 , 5, 25-40	3
1016	Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. 2010 , 6, 280-90	60
1015	Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. 2010 , 28, 353-60	91
1014	Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. 2009 , 118, 211-20	28
1013	Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus. 2010 , 65, 329-35	10
1012	Diagnostic value of poor R-wave progression in electrocardiograms for diabetic cardiomyopathy in type 2 diabetic patients. 2010 , 33, 559-64	3
1011	Diabetic cardiomyopathy--to take a long story serious. 2010 , 35, 161-8	14

1010	Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. 2010 , 53, 1033-45	101
1009	Transmitral E/A ratio decreases in association with abdominal fat accumulation in patients with impaired glucose tolerance or mild diabetes without left ventricular hypertrophy. 2010 , 25, 45-50	4
1008	Elevated troponin T on discharge predicts poor outcome of decompensated heart failure. 2010 , 25, 217-22	14
1007	Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes. 2010 , 30, 575-81	9
1006	Protective role of antioxidants in diabetes-induced cardiac dysfunction. 2010 , 10, 73-86	60
1005	Diabetic cardiomyopathy, causes and effects. 2010 , 11, 31-9	487
1004	Hyperinsulinemia improves ischemic LV function in insulin resistant subjects. 2010 , 9, 27	3
1003	Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. 2010 , 9, 63	61
1002	Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. 2010 , 200, 11-22	42
1001	Usefulness of mitral annulus velocity for the early detection of left ventricular dysfunction in a rat model of diabetic cardiomyopathy. 2010 , 18, 6-11	10
1000	Proteomics and its Application for Elucidating Insulin Deregulation in Diabetes. 2010 , 241-262	
999	. 2010 ,	4
998	Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. 2010 , 6, 883-903	127
997	Is there a link between glucose levels and heart failure? An update. 2010 , 54, 488-97	8
996	[Systemic hemodynamic and left ventricular function of diabetic-induced hypertensive rats]. 2010 , 54, 842-51	4
995	Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. 2010 , 121, 2407-18	261
994	Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. 2010 , 59, 1512-20	106
993	Oxidative stress: a key contributor to diabetic cardiomyopathy. 2010 , 88, 233-40	91

992	Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. 2010 , 299, C643-53	55
991	Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. 2010 , 121, 1209-15	61
990	Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. 2010 , 33, 2084-9	77
989	Mitochondria in the diabetic heart. 2010 , 88, 229-40	171
988	Evaluation of contractile function and inotropic reserve with tissue velocity, strain and strain rate imaging in streptozotocin-induced diabetes. 2010 , 11, 622-9	8
987	Improvement of mechanical heart function by trimetazidine in db/db mice. 2010 , 31, 560-9	28
986	Diabetic cardiomyopathy: signaling defects and therapeutic approaches. 2010 , 8, 373-91	45
985	Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. 2010 , 7, e135-e143	103
984	The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. 2010 , 55, 300-5	319
983	Cardiac disturbances in diabetes mellitus. 2010 , 17, 83-8	5
982	Diabetic cardiomyopathy. 2010 , 16, 971-9	91
981	Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. 2010 , 48, 524-9	51
980	Assessment of nonischemic myocardial fibrosis. 2010 , 56, 89-97	166
979	Effect of diabetes on alteration of metabolism in cardiac myocytes: therapeutic implications. 2011 , 13, 1155-60	31
978	Une complication mal connue du diabète : la cardiomyopathie diabétique: A poorly known complication of diabetes: Diabetic cardiomyopathy. 2011 , 5, 605-609	
977	Molecular Mechanisms in the Pathogenesis of Diabetic Cardiomyopathy. 2011 , 365-378	
976	MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. 2011 , 179, 639-50	70
975	Association of diabetes mellitus with myocardial collagen accumulation and relaxation impairment in patients with dilated cardiomyopathy. 2011 , 92, 348-55	14

974	Epigenetics and diabetic cardiomyopathy. 2011 , 94, 14-21	22
973	Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. 2011 , 76, 181-3	9
972	Endoplasmic-reticulum calcium depletion and disease. 2011 , 3,	283
971	Cardiomyopathy in diabetics: a review of current opinion on the underlying pathological mechanisms. 2011 , 27, 175-181	1
970	Altered oxido-reductive state in the diabetic heart: loss of cardioprotection due to protein disulfide isomerase. 2011 , 17, 1012-21	23
969	Morfometria das fibras colágeno cardíaco em ratos saudáveis e diabéticos suplementados com vitamina C. 2011 , 31, 1-6	3
968	Heart Failure as a Consequence of Diabetic Cardiomyopathy. 2011 , 408-418	2
967	3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats. 2011 , 6, e22777	20
966	Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice. 2011 , 38, 485-93	38
965	Positron emission tomography for the evaluation and treatment of cardiomyopathy. 2011 , 1228, 137-49	10
964	Abnormal left ventricular torsion and cardiac autonomic dysfunction in subjects with type 1 diabetes mellitus. 2011 , 60, 1115-21	24
963	Study on the protective effect of shengmai san (see text) on the myocardium in the type 2 diabetic cardiomyopathy model rat. 2011 , 31, 209-19	18
962	Multimodality imaging in diabetic heart disease. 2011 , 36, 9-47	16
961	Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. 2011 , 660, 368-74	46
960	Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2011 , 107, 615-21	3 24
959	Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. 2011 , 4, 693-702	95
958	Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca ²⁺ signaling in rat. 2011 , 43, 747-56	13
957	Effects of exercise training combined with insulin treatment on cardiac NOS1 signaling pathways in type 1 diabetic rats. 2011 , 347, 53-62	12

956	The diabetic cardiomyopathy. 2011 , 48, 173-81	120
955	Diabetic cardiomyopathy--fact or fiction?. 2011 , 36, 102-15	114
954	Peroxisome proliferator activated receptor-alpha (PPAR α) and PPAR gamma coactivator-1alpha (PGC-1 α) regulation of cardiac metabolism in diabetes. 2011 , 32, 323-8	29
953	Study on the protective effect of the Mixture of Shengmai Powder and Danshen Decoction on the myocardium of diabetic cardiomyopathy in the rat model. 2011 , 17, 116-25	10
952	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. 2011 , 10, 80	41
951	Effects of granulocyte-colony stimulating factor (G-CSF) on diabetic cardiomyopathy in Otsuka Long-Evans Tokushima fatty rats. 2011 , 10, 92	22
950	Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis. 2011 , 10, 97	29
949	Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats. 2011 , 32, 321-8	4
948	The role of PDI as a survival factor in cardiomyocyte ischemia. 2011 , 489, 47-65	31
947	Ryanodine receptor: a new therapeutic target to control diabetic cardiomyopathy. 2011 , 15, 1847-61	19
946	Studies on Experimental Models. 2011 ,	
945	. 2011 ,	
944	Heart in diabetes: not only a macrovascular disease. 2011 , 34 Suppl 2, S138-44	42
943	Junctophilin-2 expression silencing causes cardiocyte hypertrophy and abnormal intracellular calcium-handling. 2011 , 4, 214-23	80
942	Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. 2011 , 286, 11155-62	81
941	Lipotoxicity in type 2 diabetic cardiomyopathy. 2011 , 92, 10-8	133
940	Diabetes reduces left ventricular ejection fraction--irrespective of presence and extent of coronary artery disease. 2011 , 165, 945-51	18
939	Diabetic cardiomyopathy in Manipur. 2011 , 15, 204-8	1

938	Diabetic cardiomyopathy. 2011 , 11, 732-7	27
937	[Diabetes and heart failure: a practically oriented critical appraisal]. 2012 , 137, 437-41	7
936	Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. 2012 , 14, 193-201	40
935	Na ⁺ /Ca ²⁺ exchanger-1 protects against systolic failure in the Akitains2 model of diabetic cardiomyopathy via a CXCR4/NF- κ B pathway. 2012 , 303, H353-67	28
934	Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. 2012 , 122, 1109-18	230
933	Cardiac effects of HDL and its components on diabetic cardiomyopathy. 2012 , 12, 132-47	10
932	Cardiomyopathie diabétique. 2012 , 7, 1-4	
931	Diabetes in mice with monogenic obesity: the db/db mouse and its use in the study of cardiac consequences. 2012 , 933, 47-57	19
930	Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?. 2012 , 14, 1389-400	12
929	Diabetic cardiomyopathy: ongoing controversies in 2012. 2012 , 37, 880-6	16
928	Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor- β . 2012 , 30, e30-40	102
927	[Aerobic and strength training in patients with diabetes mellitus type 2 and heart failure]. 2012 , 37, 499-507	
926	Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach. 2012 , 28, 1329-39	8
925	Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. 2012 , 177, 107-15	61
924	Over-nutrition and metabolic cardiomyopathy. 2012 , 61, 1205-10	56
923	Berberine in type 2 diabetes therapy: a new perspective for an old antidiarrheal drug?. 2012 , 2, 379-386	32
922	Myocardial and metabolic dysfunction in type 2 diabetic rats: impact of ghrelin. 2012 , 90, 99-111	6
921	Cardiovascular disease and diabetes: the vulnerable patient. 2012 , 14, B4-B13	15

920	Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. 2012 , 52, 1019-26		45
919	A new scoring system for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation. <i>American Journal of Cardiology</i> , 2012 , 110, 678-82	3	28
918	Serum C-reactive protein and carotid intima-media thickness. 2012 , 156, 221-2		1
917	Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes. 2012 , 156, 219-21		10
916	Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation. 2012 , 97, 185-94		32
915	Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. 2012 , 11, 147		39
914	Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. 2012 , 11, 73		123
913	Characteristics and in-hospital outcomes of patients with acute coronary syndromes and heart failure in the United Arab Emirates. 2012 , 5, 534		4
912	Exercise-induced cardiac performance in autoimmune (type 1) diabetes is associated with a decrease in myocardial diacylglycerol. 2012 , 113, 817-26		11
911	Progression of subclinical myocardial dysfunction in type 2 diabetes after 5 years despite improved glycemic control. 2012 , 29, 1045-53		13
910	Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease--an overview. 2012 , 22, 330-5		71
909	Diabetic cardiomyopathy: bench to bedside. 2012 , 8, 619-31		89
908	Diabetic cardiomyopathy: myth or reality?. 2012 , 105, 218-25		65
907	[Heart failure and development of type 2 diabetes mellitus]. 2012 , 138, 579-83		1
906	Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels. 2012 , 464, 613-21		29
905	Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. 2012 , 18, 22-34		34
904	Aldose reductase, oxidative stress, and diabetic mellitus. 2012 , 3, 87		207
903	Autophagy contributes to retardation of cardiac growth in diabetic rats. 2012 , 28, 99-107		29

902	Insulin Resistance and Cardiomyopathy. 2012 ,	1
901	Rho kinase inhibitors: potential treatments for diabetes and diabetic complications. 2012 , 18, 2964-73	19
900	Diabetic Cardiomyopathy: Cardiac Changes, Pathophysiological Mechanisms, Biologic Markers, and the Available Therapeutic Armamentarium. 2012 ,	
899	[Assessment of diastolic function in children and adolescents with type 1 diabetes mellitus - are there early signs of diabetic cardiomyopathy?]. 2012 , 56, 226-32	0
898	The role of inflammation in diabetic cardiomyopathy. 2012 , 59	10
897	Update on diabetic cardiomyopathy: inches forward, miles to go. 2012 , 12, 305-13	28
896	FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. 2012 , 14, 549-62	30
895	Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. 2012 , 55, 1544-53	100
894	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. 2012 , 17, 325-44	240
893	A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. 2012 , 41, 398-409	46
892	Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy. 2012 , 17, 14-21	10
891	Effect of cardiovascular autonomic neuropathy (CAN) on left ventricular function in normotensive type 1 diabetic patients: A study by pulsed wave tissue Doppler echocardiography. 2012 , 64, 7-13	1
890	Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPAR α mice. 2013 , 40, 2449-59	9
889	Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1. 2013 , 67, 1397-408	84
888	Obesity-related cardiorenal disease: the benefits of bariatric surgery. 2013 , 9, 539-51	25
887	Intracellular levels of Na(+) and TTX-sensitive Na(+) channel current in diabetic rat ventricular cardiomyocytes. 2013 , 13, 138-47	16
886	Diabetes mellitus reduces the function and expression of ATP-dependent K ⁺ channels in cardiac mitochondria. 2013 , 92, 664-8	20
885	Diabetes. 2013 , 9, 157-168	1

884	Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. 2013 , 50, 597-606	28
883	[Echocardiography in diabetic cardiomyopathy]. 2013 , 38, 42-7	4
882	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38MAPK during insulin resistance. 2013 , 62, 3887-900	103
881	Protection from diabetic cardiomyopathy - putative role of the retinoid receptor-mediated signaling. 2013 , 59, 179-80	3
880	Differential changes of left ventricular myocardial deformation in diabetic patients with controlled and uncontrolled blood glucose: a three-dimensional speckle-tracking echocardiography-based study. 2013 , 26, 499-506	47
879	Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143. 2013 , 100, 201-10	49
878	Animal Models of Myocardial Disease. 2013 , 145-171	2
877	Diabetic cardiomyopathy: pathophysiology and clinical features. 2013 , 18, 149-66	298
876	Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats. 2013 , 12, 123	28
875	MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes. 2013 , 33, 834-839	24
874	The limited clinical value of a specific diabetic cardiomyopathy. 2013 , 23, 599-605	3
873	Mechanisms of diabetic complications. 2013 , 93, 137-88	1339
872	Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfunction. 2013 , 32, 571-90	78
871	Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. 2013 , 22, 117-25	65
870	Myosin heads are displaced from actin filaments in the in situ beating rat heart in early diabetes. 2013 , 104, 1065-72	10
869	Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. 2013 , 92, 669-76	56
868	Impaired translocation and activation of mitochondrial Akt1 mitigated mitochondrial oxidative phosphorylation Complex V activity in diabetic myocardium. 2013 , 59, 167-75	21
867	Diabetic cardiomyopathy and metabolic remodeling of the heart. 2013 , 92, 609-15	57

866	Predictors and prevention of diabetic cardiomyopathy. 2013 , 6, 151-60	59
865	Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. 2013 , 60, 307-17	98
864	Abnormalities of the cardiac stem and progenitor cell compartment in experimental and human diabetes. 2013 , 119, 179-87	17
863	Proteomic analysis of hearts from Akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy. 2013 , 12, 3920-33	25
862	Exercise training prevents the development of cardiac dysfunction in the low-dose streptozotocin diabetic rats fed a high-fat diet. 2013 , 91, 80-9	30
861	(1)H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism. 2013 , 18, 657-68	29
860	3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model. 2013 , 8, 989-94	9
859	Blockage of peripheral NPY Y1 and Y2 receptors modulates baroreflex sensitivity of diabetic rats. 2013 , 31, 421-31	6
858	Diallyl trisulfide and diallyl disulfide ameliorate cardiac dysfunction by suppressing apoptotic and enhancing survival pathways in experimental diabetic rats. 2013 , 114, 402-10	33
857	Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiotensin-2 upregulation. 2013 , 113, 1331-44	81
856	Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression. 2013 , 14, 15724-39	23
855	Taurine attenuates oxidative stress and alleviates cardiac failure in type I diabetic rats. 2013 , 54, 171-9	49
854	The effect of carvedilol on blood glucose levels in normal albino rats. 2013 , 7, 1900-3	2
853	A Drosophila model of high sugar diet-induced cardiomyopathy. 2013 , 9, e1003175	155
852	Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. 2013 , 6, 364-70	45
851	Investigation of the Protective Effects of Phlorizin on Diabetic Cardiomyopathy in db/db Mice by Quantitative Proteomics. 2013 , 2013, 263845	35
850	Diabetic basement membrane thickening does not occur in myocardial capillaries of transgenic mice when metallothionein is overexpressed in cardiac myocytes. 2013 , 296, 480-7	9
849	Coronary flow reserve and myocardial performance index in newly diagnosed diabetic patients. 2013 , 30, 1164-71	6

848	Diabetes-Associated Cardiomyopathy and Cell Therapy. 2013 , 211-232	1
847	Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. 2013 , 4, 177-89	104
846	Intervention study on Chinese medicine Tongxinluo for cardiomyopathy in diabetic rats. 2013 , 7, 172-178	1
845	Stereological study of the diabetic heart of male rats. 2013 , 29, 12-8	4
844	Left ventricular dysfunction in normotensive type II diabetic patients in Port Harcourt, Nigeria. 2013 , 9, 529-33	8
843	Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy. 2013 , 46, 251-5	6
842	Mice long-term high-fat diet feeding recapitulates human cardiovascular alterations: an animal model to study the early phases of diabetic cardiomyopathy. 2013 , 8, e60931	97
841	Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes. 2013 , 8, e72080	58
840	Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. 2013 , 13, 38-50	20
839	Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies. 2013 , 19, 4806-17	88
838	Potential Target Molecules in Diabetic Cardiomyopathy: Hepatocyte Growth Factor (HGF) and Ryanodine Receptor 2 (RyR2). 2013 ,	
837	Influence of naringin on the myocardial ultrastructure and NF- κ B expression in rats with diabetic cardiomyopathy. 2013 , 7, 439-443	3
836	Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice. 2014 , 9, e85078	35
835	Garlic attenuates cardiac oxidative stress via activation of PI3K/AKT/Nrf2-Keap1 pathway in fructose-fed diabetic rat. 2014 , 9, e94228	98
834	Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling. 2014 , 3, 566-94	15
833	Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3 β signaling pathway in the rat model. 2014 , 19, 14782-93	32
832	Design, Synthesis and Antidiabetic, Cardiomyopathy Studies of Cinnamic Acid-Amino Acid Hybrid Analogs. 2014 , 04,	1
831	Enhancement of cellular antioxidant-defence preserves diastolic dysfunction via regulation of both diastolic Zn ²⁺ and Ca ²⁺ and prevention of RyR2-leak in hyperglycemic cardiomyocytes. 2014 , 2014, 290381	25

830	Endothelial Function in Pre-diabetes, Diabetes and Diabetic Cardiomyopathy: A Review. 2014 , 05,	9
829	Speckle tracking echocardiography in the diagnosis of early left ventricular systolic dysfunction in type II diabetic mice. 2014 , 14, 141	27
828	Cardiomyocyte changes in the metabolic syndrome and implications for endogeneous protective strategies. 2014 , 12, 331-43	1
827	The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. 2014 , 12, 345-58	33
826	Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. 2014 , 2014, 847827	66
825	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. 2014 , 126, 471-82	59
824	Diastolic function of the right ventricle is impaired in experimental type 2 diabetic rat models. 2014 , 44, 448-53	5
823	The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. 2014 , 15, 1368-76	41
822	Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage. 2014 , 5, 623-34	124
821	Application of a novel curcumin analog in the management of diabetic cardiomyopathy. 2014 , 63, 3166-8	15
820	Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation. 2014 , 13, 100	42
819	Hyperglycemia has a greater impact on left ventricle function in South Asians than in Europeans. 2014 , 37, 1124-31	15
818	Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction. 2014 , 186, 22-31	35
817	Diabetic heart disease: insights from cardiac mechanics. 2014 , 27, 489-92	4
816	Treatment of Diabetic Cardiomyopathy through Upregulating Autophagy by Stimulating AMP-Activated Protein Kinase. 2014 , 91-103	
815	Vascular imaging in diabetes. 2014 , 16, 399	1
814	Molecular mechanisms of diabetic cardiomyopathy. 2014 , 57, 660-71	502
813	Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. 2014 , 57, 672-80	59

812	The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. 2014 , 20, 304-9	88
811	The interplay between autophagy and apoptosis in the diabetic heart. 2014 , 71, 71-80	99
810	Sudden cardiac death and diabetes mellitus. 2014 , 28, 573-9	26
809	Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. 2014 , 386, 233-49	54
808	Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. 2014 , 142, 375-415	354
807	Diabetic Cardiomyopathy. 2014 ,	2
806	Calcium signaling in diabetic cardiomyocytes. 2014 , 56, 372-80	53
805	Coronary triglyceride deposition in contemporary advanced diabetics. 2014 , 64, 325-35	18
804	Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. 2014 , 77, 42-52	124
803	Quantitative proteomics study of protective effects of grape seed procyanidin B2 on diabetic cardiomyopathy in db/db mice. 2014 , 78, 1577-83	15
802	Combined metoprolol and ascorbic acid treatment prevents intrinsic damage to the heart during diabetic cardiomyopathy. 2014 , 92, 827-37	6
801	Mitochondrial inefficiencies and anoxic ATP hydrolysis capacities in diabetic rat heart. 2014 , 307, C499-507	58
800	Diabetic Cardiomyopathy: Distinct and Preventable Entity or Inevitable Consequence?. 2014 , 8, 1	1
799	Progressive decay of Ca ²⁺ homeostasis in the development of diabetic cardiomyopathy. 2014 , 13, 75	35
798	The cardioprotective effect of an aqueous extract of fermented rooibos (<i>Aspalathus linearis</i>) on cultured cardiomyocytes derived from diabetic rats. 2014 , 21, 595-601	43
797	The relationships between cardiovascular disease and diabetes: focus on pathogenesis. 2014 , 43, 41-57	51
796	Effects of non-dipper blood pressure pattern on left ventricular rotational mechanics in hypertensive patients with type 2 diabetes mellitus: a speckle tracking study. 2014 , 30, 57-65	8
795	MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems. 2014 , 211, 491-500	26

794	Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy. 2014 , 19, 75-86	21
793	Role of microangiopathy in diabetic cardiomyopathy. 2014 , 19, 25-33	58
792	Diabetes-related heart failure. 2014 , 78, 576-83	46
791	Role of Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 in myocardial cells in diabetes. 2015 , 10, 67-73	7
790	Lessons and Perspectives on Heart Failure Management From Considerations Based on the CHART-2 Study. 2015 , 79, 1689-90	1
789	Rutin administration attenuates myocardial dysfunction in diabetic rats. 2015 , 14, 90	31
788	Left ventricular diastolic dysfunction in nonhuman primate model of dysmetabolism and diabetes. 2015 , 15, 141	11
787	Administration of granulocyte-colony stimulating factor accompanied with a balanced diet improves cardiac function alterations induced by high fat diet in mice. 2015 , 15, 162	8
786	Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. 2015 , 14, 83	37
785	Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension. 2015 , 14, 92	11
784	The vulnerable myocardium. Diabetic cardiomyopathy. 2015 , 35, 17-24	16
783	Effect of intermittent hypoxia on the cardiac HIF-1/VEGF pathway in experimental type 1 diabetes mellitus. 2016 , 16, 76-83	10
782	Diabetic Cardiomyopathy; Summary of 41 Years. 2015 , 45, 266-72	50
781	Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients. 2015 , 2015, 743503	19
780	Low Intensity Physical Exercise Attenuates Cardiac Remodeling and Myocardial Oxidative Stress and Dysfunction in Diabetic Rats. 2015 , 2015, 457848	29
779	Cardiac H ₂ S Generation Is Reduced in Ageing Diabetic Mice. 2015 , 2015, 758358	55
778	Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice. 2015 , 8, 788-98	70
777	Targeting caveolin-3 for the treatment of diabetic cardiomyopathy. 2015 , 151, 50-71	14

776	Ginsenoside Rg1 ameliorates oxidative stress and myocardial apoptosis in streptozotocin-induced diabetic rats. 2015 , 16, 344-54	40
775	Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. 2015 , 101, 1061-6	93
774	Effects of the association of diabetes and pulmonary emphysema on cardiac structure and function in rats. 2015 , 96, 350-7	
773	The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. 2015 , 29, 499-507	13
772	Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. 2015 , 14, 99	74
771	Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor β . 2015 , 131, 795-804	86
770	Enhanced skeletal muscle expression of extracellular superoxide dismutase mitigates streptozotocin-induced diabetic cardiomyopathy by reducing oxidative stress and aberrant cell signaling. 2015 , 8, 188-97	25
769	Morphological restructuring of myocardium during the early phase of experimental diabetes mellitus. 2015 , 298, 396-407	6
768	Hydrogen sulfide attenuates high fat diet-induced cardiac dysfunction via the suppression of endoplasmic reticulum stress. 2015 , 46, 145-56	66
767	Mitochondrial dynamics in diabetic cardiomyopathy. 2015 , 22, 1545-62	63
766	Impact of 1, 25-(OH)2D3 on Left Ventricular Hypertrophy in Type 2 Diabetic Rats. 2015 , 30, 114-20	2
765	Relationship between increased left atrial volume and microvascular complications in patients with type 2 diabetes. 2015 , 29, 822-8	9
764	Mitochondrial complex I defect and increased fatty acid oxidation enhance protein lysine acetylation in the diabetic heart. 2015 , 107, 453-65	57
763	The role of CaMKII in diabetic heart dysfunction. 2015 , 20, 589-600	23
762	Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK. 2015 , 412, 85-94	82
761	Effect and mechanisms of zinc supplementation in protecting against diabetic cardiomyopathy in a rat model of type 2 diabetes. 2015 , 15, 14-20	15
760	Activation of Foxo1 by insulin resistance promotes cardiac dysfunction and β -myosin heavy chain gene expression. 2015 , 8, 198-208	54
759	Delayed longitudinal myocardial function recovery after dobutamine challenge as a novel presentation of myocardial dysfunction in type 2 diabetic patients without angiographic coronary artery disease. 2015 , 16, 676-83	7

758	Relaxin-2 does not ameliorate nephropathy in an experimental model of type-1 diabetes. 2015 , 40, 77-88	10
757	Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 study. 2015 , 8, 400-410	67
756	High glucose induces mitochondrial dysfunction independently of protein O-GlcNAcylation. 2015 , 467, 115-26	31
755	Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. 2015 , 36, 1718-27, 1727a-1727c	294
754	FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. 2015 , 19, 1557-68	60
753	Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes. 2015 , 16, 1000-7	34
752	Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. 2015 , 22, 1606-30	35
751	Diabetic cardiomyopathy and the role of mitochondrial dysfunction: novel insights, mechanisms, and therapeutic strategies. 2015 , 22, 1499-501	14
750	Impaired fasting glucose and left ventricular diastolic dysfunction in middle-age adults: a retrospective cross-sectional analysis of 2971 subjects. 2015 , 14, 119	17
749	Diabète et insuffisance cardiaque : la cardiomyopathie diabétique. 2015 , 9, 377-384	
748	Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. 2015 , 8, 448-54	47
747	Elevated expression of periostin in diabetic cardiomyopathy and the effect of valsartan. 2015 , 15, 90	23
746	Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes. 2016 , 65, 44-52	125
745	Metabolic abnormalities of the heart in type II diabetes. 2015 , 12, 239-48	26
744	Protective effects of desacyl ghrelin on diabetic cardiomyopathy. 2015 , 52, 293-306	37
743	Alterations in connexin 43 during diabetic cardiomyopathy: competition of tyrosine nitration versus phosphorylation. 2015 , 7, 250-259	21
742	Autophagy and oxidative stress in cardiovascular diseases. 2015 , 1852, 243-51	147
741	Endoplasmic reticulum stress and protein quality control in diabetic cardiomyopathy. 2015 , 1852, 209-18	90

740	Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. 2015 , 1852, 1155-77	204
739	Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. 2015 , 1852, 232-42	192
738	Exercise Training Attenuates Upregulation of p47(phox) and p67(phox) in Hearts of Diabetic Rats. 2016 , 2016, 5868913	10
737	Role of Mammalian Target of Rapamycin (mTOR) in Cardiac Homeostasis in Metabolic Disorders. 2016 , 263-274	
736	Present Insights on Cardiomyopathy in Diabetic Patients. 2016 , 12, 384-395	22
735	Type 2 Diabetes and Heart Failure: Challenges and Solutions. 2016 , 12, 249-55	42
734	Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives. 2016 , 2016, 6143129	29
733	Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. 2016 , 2016, 8917578	45
732	Curcumin Protects Neonatal Rat Cardiomyocytes against High Glucose-Induced Apoptosis via PI3K/Akt Signalling Pathway. 2016 , 2016, 4158591	40
731	Oxidative Stress in Diabetes: Molecular Basis for Diet Supplementation. 2016 , 65-72	4
730	Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?. 2016 , 17,	82
729	Parenchymal and Stromal Cells Contribute to Pro-Inflammatory Myocardial Environment at Early Stages of Diabetes: Protective Role of Resveratrol. 2016 , 8,	10
728	Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki rats. 2016 , 15, 110	20
727	Heart Failure as a Comorbidity of Diabetes: Role of Dipeptidyl Peptidase 4. 2016 , 23, 147-54	9
726	Diabetic Cardiomyopathy: A Forensic Perspective. 2016 , 6, 191-197	2
725	Cardiovascular Action of Insulin in Health and Disease: Endothelial L-Arginine Transport and Cardiac Voltage-Dependent Potassium Channels. 2016 , 7, 74	13
724	Ablation of Matrix Metalloproteinase-9 Prevents Cardiomyocytes Contractile Dysfunction in Diabetics. 2016 , 7, 93	17
723	New Molecular Insights of Insulin in Diabetic Cardiomyopathy. 2016 , 7, 125	59

722	Mitochondrial Peroxiredoxin-3 protects against hyperglycemia induced myocardial damage in Diabetic cardiomyopathy. 2016 , 97, 489-500	31
721	Sequential changes in autophagy in diabetic cardiac fibrosis. 2016 , 13, 327-32	9
720	Cell mechanics as a marker for diseases: Biomedical applications of AFM. 2016 ,	35
719	Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. 2016 , 16, 242	16
718	Congestive Heart Failure. 2016 , 659-672	
717	LCZ696, an angiotensin receptor-nepriylisin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. 2016 , 18, 386-93	94
716	Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. 2016 , 118, 21-8	23
715	Diabetic cardiomyopathy: role of the E3 ubiquitin ligase. 2016 , 310, E473-83	12
714	Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway. 2016 , 153, 55-65	10
713	Oncostatin M-induced cardiomyocyte dedifferentiation regulates the progression of diabetic cardiomyopathy through B-Raf/Mek/Erk signaling pathway. 2016 , 48, 257-65	14
712	Myocardial dysfunction and cardiovascular disease in type 2 diabetes. 2016 , 76, 271-81	12
711	Novel insight into the dangerous connection between diabetes and heart failure. 2016 , 41, 201-7	9
710	Gene expression profiling in hearts of diabetic mice uncovers a potential role of estrogen-related receptor β in diabetic cardiomyopathy. 2016 , 430, 77-88	8
709	Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes?. 2016 , 46, 947-953	42
708	Rosmarinic Acid suppressed high glucose-induced apoptosis in H9c2 cells by ameliorating the mitochondrial function and activating STAT3. 2016 , 477, 1024-1030	19
707	Low-dose radiation prevents type 1 diabetes-induced cardiomyopathy via activation of AKT mediated anti-apoptotic and anti-oxidant effects. 2016 , 20, 1352-66	22
706	Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. 2016 , 130, 625-41	97
705	Lack of miR-133a Decreases Contractility of Diabetic Hearts: A Role for Novel Cross Talk Between Tyrosine Aminotransferase and Tyrosine Hydroxylase. 2016 , 65, 3075-90	35

704	Relation of Early and Late Stages of Glucose Metabolism Disturbances With Left Ventricular Geometry and Function: Are Sugar Kisses Bad for the Heart?. 2016 , 9,	
703	Disruption of calcium homeostasis by cardiac-specific over-expression of PPAR- β in mice: A role in ventricular arrhythmia. 2016 , 167, 12-21	11
702	lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. 2016 , 6, 36340	129
701	The influence of type 2 diabetes and arterial hypertension on right ventricular layer-specific mechanics. 2016 , 53, 791-7	19
700	Effects of Tongxinluo on myocardial fibrosis in diabetic rats. 2016 , 79, 130-6	6
699	Assessment of left ventricular function in young type 1 diabetes mellitus patients by two-dimensional speckle tracking echocardiography: Relation to duration and control of diabetes. 2016 , 68, 217-225	4
698	Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study. 2016 , 13, 260-7	11
697	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. 2016 , 133, 2459-502	520
696	MicroRNA transport in cardiovascular complication of diabetes. 2016 , 1861, 2111-2120	15
695	Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. 2016 , 12, 144-53	383
694	Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by aFGF-Loaded Heparin-Modified Microbubbles and UTMD Technique. 2016 , 30, 247-61	19
693	Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. 2016 , 90, 84-93	242
692	LXR β improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. 2016 , 59, 634-43	26
691	Histological and proteomic profile of diabetic versus non-diabetic dilated cardiomyopathy. 2016 , 203, 282-9	12
690	Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy. 2016 , 38, 10-22	12
689	Effects of Low Intensity Exercise Against Apoptosis and Oxidative Stress in Streptozotocin-induced Diabetic Rat Heart. 2017 , 125, 583-591	18
688	Type 2 diabetes mellitus correlates with systolic function during myocardial stress perfusion scanning with Nitrogen-13 ammonia PET. 2017 , 24, 1305-1311	5
687	The complex principle of cause and effect. 2017 , 24, 1312-1313	

686	The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. 2017 , 66, 1030-1040	84
685	The long and unfinished journey of hyperglycaemia and heart failure research. 2017 , 103, 331-332	
684	Diagnostic approaches for diabetic cardiomyopathy. 2017 , 16, 28	111
683	Heart failure and diabetes - underestimated, underdiagnosed and poorly understood: A call for action. 2017 , 14, 67-68	5
682	Novel insights into DNA methylation and its critical implications in diabetic vascular complications. 2017 , 37,	17
681	[Diabetes and heart failure : Update 2017]. 2017 , 42, 329-340	0
680	Mir30c Is Involved in Diabetic Cardiomyopathy through Regulation of Cardiac Autophagy via BECN1. 2017 , 7, 127-139	34
679	Linolenic acid and exercise training independently, and additively, decrease blood pressure and prevent diastolic dysfunction in obese Zucker rats. 2017 , 595, 4351-4364	12
678	Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts. 2017 , 18, 171-178	11
677	DUSP-1 gene expression is not regulated by promoter methylation in diabetes-associated cardiac hypertrophy. 2017 , 11, 147-154	6
676	The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus. 2017 , 17, 38	31
675	Age-dependent development of left ventricular wall thickness in type 2 diabetic (db/db) mice is associated with elevated low-density lipoprotein and triglyceride serum levels. 2017 , 32, 1025-1031	9
674	Cats with diabetes mellitus have diastolic dysfunction in the absence of structural heart disease. 2017 , 225, 50-55	7
673	Are targeted therapies for diabetic cardiomyopathy on the horizon?. 2017 , 131, 897-915	48
672	Diabetes Mellitus and Heart Failure. 2017 , 130, S40-S50	77
671	Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. 2017 , 14, 423-433	25
670	Metabolic Remodeling in Diabetic Cardiomyopathy. 2017 , 113, 422-430	69
669	Diabetes Mellitus and Heart Failure. <i>American Journal of Cardiology</i> , 2017 , 120, S37-S47	3 98

668	Pathophysiological Fundamentals of Diabetic Cardiomyopathy. 2017 , 7, 693-711	50
667	Palmitate mediated diacylglycerol accumulation causes endoplasmic reticulum stress, Plin2 degradation, and cell death in H9C2 cardiomyoblasts. 2017 , 354, 85-94	27
666	Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. 2017 , 58, R225-R240	30
665	Insulin receptor substrate signaling controls cardiac energy metabolism and heart failure. 2017 , 233, R131-R143	44
664	Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. 2017 , 1863, 2070-2077	46
663	Aleglitazar, a dual peroxisome proliferator-activated receptor- α and - β agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. 2017 , 14, 152-162	7
662	Role of microRNAs in the pathogenesis of diabetic cardiomyopathy. 2017 , 6, 140-145	19
661	Glucose variability aggravates cardiac fibrosis by altering AKT signalling path. 2017 , 14, 327-335	29
660	Cardiac oxidative stress in diabetes: Mechanisms and therapeutic potential. 2017 , 172, 50-62	148
659	Glucose transporters in healthy heart and in cardiac disease. 2017 , 230, 70-75	73
658	The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. 2017 , 32, 618-627	49
657	Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications. 2017 , 116, 45-56	35
656	BRD7 mediates hyperglycaemia-induced myocardial apoptosis via endoplasmic reticulum stress signalling pathway. 2017 , 21, 1094-1105	24
655	Exercise for Cardiovascular Disease Prevention and Treatment. 2017 ,	1
654	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. 2018 , 1067, 197-217	35
653	Transforming growth factor beta (TGF- β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. 2017 , 133, 124-130	108
652	Exercise Amaliorates Metabolic Disturbances and Oxidative Stress in Diabetic Cardiomyopathy: Possible Underlying Mechanisms. 2017 , 999, 207-230	17
651	Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy. 2017 , 7, 13514	42

650 Cardiomiopatia diabetica: finzione o realtà **2017**, 18, 231-235

649	Pathological Effects of Exosomes in Mediating Diabetic Cardiomyopathy. 2017 , 998, 113-138	23
648	Biological properties of cardiac mesenchymal stem cells in rats with diabetic cardiomyopathy. 2017 , 188, 45-52	8
647	Alterations of relaxin and its receptor system components in experimental diabetic cardiomyopathy rats. 2017 , 370, 297-304	4
646	Impact of diabetes on heart failure incidence in adults with ischemic heart disease. 2017 , 31, 1597-1601	3
645	Activation of the signaling pathway by hyperglycemia induces cardiac remodeling and dysfunction in adult zebrafish. 2017 , 10, 1217-1227	12
644	miRNAs: Nanomachines That Micromanage the Pathophysiology of Diabetes Mellitus. 2017 , 82, 199-264	10
643	Noninvasive Cardiac Imaging and the Prediction of Heart Failure Progression in Preclinical Stage A/B Subjects. 2017 , 10, 1504-1519	12
642	Impact of left ventricular longitudinal functional mechanics on the progression of diastolic function in diabetes mellitus. 2017 , 33, 1905-1914	13
641	Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression. 2017 , 31, 255-267	18
640	The effect of Astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose -stimulated H9C2 cells. 2017 , 17, 310	33
639	Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review. 2017 , 6, 96	20
638	Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. 2017 , 57, 464-473	41
637	Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial β -oxidation in cardiomyocytes via activation of the cardiac renin-angiotensin system and induction of miR-208a. 2017 , 112, 2	34
636	1,25(OH) D improves cardiac dysfunction, hypertrophy, and fibrosis through PARP1/SIRT1/mTOR-related mechanisms in type 1 diabetes. 2017 , 61, 1600338	24
635	Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. 2017 , 19, 80-87	4
634	Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. 2017 , 32, 446-457	5
633	The Effects of Carvedilol on Cardiac Function and the AKT/XIAP Signaling Pathway in Diabetic Cardiomyopathy Rats. 2017 , 136, 204-211	8

632	Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation. 2018 , 15, 75-84	10
631	Undiagnosed and diagnosed diabetes mellitus among hospitalised acute heart failure patients in Botswana. 2017 , 5, 2050312117731473	7
630	Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway. 2018 , 15, 691-698	11
629	A COMPREHENSIVE STUDY ON LITERATURE EVIDENCE, CLINICAL STUDIES AND PRACTICES OF HERBAL DRUGS FOR DIABETIC NEUROPATHY AND CARDIOMYOPATHY. 2017 , 10, 30	
628	Heart failure: an underestimated therapeutic target in diabetes. 2018 , 7, 10-12	2
627	Diabetic Cardiomyopathy: Focus on Oxidative Stress, Mitochondrial Dysfunction and Inflammation. 2017 ,	6
626	Combination of Morroniside and Diosgenin Prevents High Glucose-Induced Cardiomyocytes Apoptosis. 2017 , 22,	24
625	Diabetic Cardiomyopathy: An Immunometabolic Perspective. 2017 , 8, 72	48
624	New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. 2017 , 2017, 1253425	8
623	Hawthorn Leaf Flavonoids Protect against Diabetes-Induced Cardiomyopathy in Rats via PKC-Signaling Pathway. 2017 , 2017, 2071952	10
622	The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas. 2017 , 2017, 5343972	16
621	Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2 Expression. 2017 , 22,	43
620	Red blood cell distribution width as a prognostic marker in patients with heart failure and diabetes mellitus. 2017 , 16, 81	30
619	Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy. 2017 , 16, 82	5
618	Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-β-D-glucoside. 2017 , 14, 45	48
617	The Impact of Autophagy on Cardiovascular Senescence and Diseases. 2017 , 58, 666-673	38
616	Evaluation of Cardiac Functions in Children and Adolescents with Type 1 Diabetes. 2017 , 25, 12-19	7
615	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. 2018 , 23, 303-323	27

614	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. 2018 , 20, 853-872	264
613	Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy. 2018 , 34, 605-614	32
612	From cell to heart: the impact of the cell organelles dysfunction on heart disease. 2018 , 19, 131-140	0
611	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. 2018 , 34, 632-643	41
610	A Systematic Review on the Protective Effect of N-Acetyl Cysteine Against Diabetes-Associated Cardiovascular Complications. 2018 , 18, 283-298	33
609	Miocardopatía diabética: un punto de vista retrospectivo. 2018 , 25, 51-54	
608	Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats. 2018 , 6, e13612	4
607	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. 2018 , 178, R127-R139	33
606	Evaluating the impact of diabetes and diabetic cardiomyopathy rat heart on the outcome of ischemia-reperfusion associated oxidative stress. 2018 , 118, 35-43	19
605	Protection by dimethyl fumarate against diabetic cardiomyopathy in type 1 diabetic mice likely via activation of nuclear factor erythroid-2 related factor 2. 2018 , 287, 131-141	24
604	Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. 2018 , 122, 624-638	613
603	Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. 2018 , 71, 339-351	138
602	Clinical impact of oral antidiabetic medications in heart failure patients. 2018 , 23, 325-335	7
601	Keeping the right track in the treatment of patients with type 2 diabetes. 2018 , 20, 52-54	2
600	Left ventricular systolic dysfunction predicts long-term major microvascular complication outcomes in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood onset diabetes. 2018 , 32, 298-304	1
599	Fragmented QRS complexes are associated with left ventricular dysfunction in patients with type-2 diabetes mellitus: a two-dimensional speckle tracking echocardiography study. 2018 , 73, 449-456	7
598	Hyperpolarised magnetic resonance for in vivo real-time metabolic imaging. 2018 , 104, 1484-1491	15
597	Melatonin therapy for diabetic cardiomyopathy: A mechanism involving Syk-mitochondrial complex I-SERCA pathway. 2018 , 47, 88-100	94

596	Dyspnoe bei Diabetes und Herzinsuffizienz. 2018 , 14, 36-43	1
595	Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. 2018 , 17, 43	35
594	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. 2018 , 43, 68-110	15
593	MicroRNA and Diabetic Complications: A Clinical Perspective. 2018 , 29, 1041-1063	18
592	Diabetes Mellitus and Exercise Physiology in the Presence of Diabetic Comorbidities. 2018 , 255-287	
591	MG53 and disordered metabolism in striated muscle. 2018 , 1864, 1984-1990	6
590	Ursolic acid ameliorates oxidative stress, inflammation and fibrosis in diabetic cardiomyopathy rats. 2018 , 97, 1461-1467	49
589	Left atrium passive ejection fraction is the most sensitive index of type 2 diabetes mellitus-related cardiac changes. 2018 , 34, 141-151	4
588	Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. 2018 , 61, 21-28	268
587	Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. 2018 , 17, 6887-6892	18
586	Echocardiographic feature of diabetic cardiomyopathy: where are we now?. 2018 , 8, 47-56	18
585	Cardiac Fibroblast. 2018 , 420-433	1
584	Cardiomyopathie du diabète : nouvelles données physiopathologiques. 2018 , 12, 657-662	
583	Early Detection of Diastolic Dysfunction in Diabetic Patients (Single Center Cross Sectional Study). 2018 , 02,	1
582	OBSOLETE: Cardiac Fibroblast. 2018 ,	
581	PGC-1 β s a Pivotal Factor in Lipid and Metabolic Regulation. 2018 , 19,	134
580	Chronic O-GlcNAcylation and Diabetic Cardiomyopathy: The Bitterness of Glucose. 2018 , 9, 642	41
579	Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. 2018 , 9, 1514	80

578	Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF- κ B. 2018 , 9, 2996	22
577	Effect of Astragalus Polysaccharides on Cardiac Dysfunction in db/db Mice with Respect to Oxidant Stress. 2018 , 2018, 8359013	11
576	Evaluation of tissue Doppler ultrasonographic and strain imaging for assessment of myocardial dysfunction in dogs with type 1 diabetes mellitus. 2018 , 79, 1035-1043	2
575	Insulin Resistance and Vulnerability to Cardiac Ischemia. 2018 , 67, 2695-2702	19
574	Fibroblast growth factor 19 improves cardiac function and mitochondrial energy homeostasis in the diabetic heart. 2018 , 505, 242-248	6
573	MiR-133a Mimic Alleviates T1DM-Induced Systolic Dysfunction in Akita: An MRI-Based Study. 2018 , 9, 1275	16
572	Silencing of NOD2 protects against diabetic cardiomyopathy in a murine diabetes model. 2018 , 42, 3017-3026	5
571	Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats. 2018 , 2018, 9232065	17
570	Uncoupling proteins as a therapeutic target to protect the diabetic heart. 2018 , 137, 11-24	15
569	Changes of cardiac function in diabetic dogs. 2018 , 20, 438-450	1
568	Combined aerobic and resistance exercise training attenuates cardiac dysfunctions in a model of diabetes and menopause. 2018 , 13, e0202731	7
567	Downregulation of microRNA-1 attenuates glucose-induced apoptosis by regulating the liver X receptor β in cardiomyocytes. 2018 , 16, 1814-1824	8
566	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. 2018 , 15, 494-503	21
565	Long noncoding RNAs: A new player in the prevention and treatment of diabetic cardiomyopathy?. 2018 , 34, e3056	14
564	Physiology and Pathology of Mitochondrial Dehydrogenases. 2018 ,	2
563	Assessment of left ventricular systolic function by tissue Doppler imaging in controlled versus uncontrolled type 2 diabetic patients. 2018 , 70, 203-211	1
562	Histones and heart failure in diabetes. 2018 , 75, 3193-3213	14
561	Rapid Screening and Quantitative Determination of Active Components in Qing-Hua-Yu-Re-Formula Using UHPLC-Q-TOF/MS and HPLC-UV. 2018 , 2018, 8535127	6

560	Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications. 2018 , 9, 114	102
559	Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures. 2018 , 9, 453	20
558	LncRNAs: Proverbial Genomic "Junk" or Key Epigenetic Regulators During Cardiac Fibrosis in Diabetes?. 2018 , 5, 28	13
557	Autophagy: A New Therapeutic Target. 2018 , 277-285	
556	Novel approaches in the treatment of diabetic cardiomyopathy. 2018 , 106, 1039-1045	9
555	Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy. 2018 , 1056, 47-59	10
554	Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial. 2018 , 10, 19	2
553	EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice. 2018 , 210, 29-39	7
552	ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications. 2018 , 314, E191-E200	30
551	Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes. 2018 , 9, 855	5
550	Mechanisms and treatment of heart failure in diabetes. 2018 , 35, 117-122a	
549	Gene expression profiles of rat MMECs with different glucose levels and fgl2 gene silencing. 2018 , 34, e3058	
548	Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. 2019 , 40, 1-8	80
547	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. 2019 , 45, 238-247	27
546	Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study. 2019 , 451, 69-78	9
545	Growth Differentiation Factor-15 Level and Tissue Doppler Echocardiography as a Tool in Identification of Cardiac Effects in the Children with Type 1 Diabetes Mellitus. 2021 , 129, 574-580	0
544	The Further Negative Effect of Hyperuricemia on Left Ventricular Structure and Function in Patients with Type 2 Diabetes Mellitus: A Transthoracic 3D Speckle Tracking Imaging Study. 2019 , 17, 436-443	5
543	Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice. 2019 , 23, 6319-6330	21

542	Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose-induced injury in cardiomyocytes. 2019 , 23, 6393-6402	7
541	Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. 2019 , 20,	40
540	Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation. 2019 , 33, 2737-2748	20
539	Reactive Carbonyl Species: Diabetic Complication in the Heart and Lungs. 2019 , 30, 546-556	11
538	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. 2019 , 20,	47
537	Improvement of insulin signalling rescues inflammatory cardiac dysfunction. 2019 , 9, 14801	2
536	Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. 2019 , 62, 2354-2364	9
535	Established and Emerging Mechanisms of Diabetic Cardiomyopathy. 2019 , 8, 26-47	6
534	Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study. 2019 , 19, 89	7
533	Carbonic anhydrase II/sodium-proton exchanger 1 metabolon complex in cardiomyopathy of ob type 2 diabetic mice. 2019 , 136, 53-63	5
532	Prevalence of diabetic macrovascular complications and related factors from 2005 to 2014 in Taiwan: A nationwide survey. 2019 , 118 Suppl 2, S96-S102	6
531	Changes in Cardiac Morphology and Function in Individuals With Diabetes Mellitus: The UK Biobank Cardiovascular Magnetic Resonance Substudy. 2019 , 12, e009476	20
530	Diabetes, heart failure, and renal dysfunction: The vicious circles. 2019 , 62, 298-302	61
529	Luteolin protects against diabetic cardiomyopathy by inhibiting NF- κ B-mediated inflammation and activating the Nrf2-mediated antioxidant responses. 2019 , 59, 152774	77
528	Hydrogen sulfide preconditioning could ameliorate reperfusion associated injury in diabetic cardiomyopathy rat heart through preservation of mitochondria. 2019 , 158, 208-216	7
527	The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. 2019 , 8,	13
526	A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction. 2019 , 10, 1145-1147	2
525	Non-coding RNA involvement in the pathogenesis of diabetic cardiomyopathy. 2019 , 23, 5859-5867	29

524	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. 2019 , 140, e294-e324	168
523	A review of fibroblast growth factor 21 in diabetic cardiomyopathy. 2019 , 24, 1005-1017	15
522	Diabetic cardiomyopathy: acute and reversible left ventricular systolic dysfunction due to cardiotoxicity of hyperglycaemic hyperosmolar state-a case report 2019 , 3,	2
521	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. 2019 , 25, 584-619	30
520	The Biology of Senescence. 2019 ,	
519	Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder. 2019 , 14, 134	20
518	Contribution of Impaired Insulin Signaling to the Pathogenesis of Diabetic Cardiomyopathy. 2019 , 20,	25
517	Cardiovascular Manifestations of Mitochondrial Disease. 2019 , 8,	7
516	Transgenic Expression of miR-133a in the Diabetic Akita Heart Prevents Cardiac Remodeling and Cardiomyopathy. 2019 , 6, 45	13
515	Role of Mitochondria in Cardiovascular Comorbidities Associated with Obesity and Type 2 Diabetes. 2019 , 263-286	
514	Diabetic Cardiomyopathy. 2019 , 124, 1160-1162	139
513	Cardiomyocyte mitochondrial dysfunction in diabetes and its contribution in cardiac arrhythmogenesis. 2019 , 46, 6-14	10
512	Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice. 2019 , 20,	17
511	Heart failure and diabetes: management and open issues. 2019 , 44, 203-209	1
510	Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. 2019 , 21, 1780-1789	17
509	Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress. 2019 , 139, 311-318	16
508	Molecular Imaging to Monitor Left Ventricular Remodeling in Heart Failure. 2019 , 12, 1	3
507	Diabetic cardiomyopathy - A comprehensive updated review. 2019 , 62, 315-326	72

506	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. 2019 , 10, 2042018819834869	39
505	Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications. 2019 , 15, 341-347	65
504	Variations in glucose/C-peptide ratio in patients with type 2 diabetes associated with renal function. 2019 , 150, 1-7	2
503	Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms. 2019 , 20,	9
502	Heart failure and its complications in patients with diabetes: Mounting evidence for a growing burden. 2019 , 26, 106-113	7
501	-Acetyl cysteine ameliorates hyperglycemia-induced cardiomyocyte toxicity by improving mitochondrial energetics and enhancing endogenous Coenzyme Q levels. 2019 , 6, 1240-1245	14
500	Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. 2019 , 74, 235-245	8
499	Activation of TGR5 Partially Alleviates High Glucose-Induced Cardiomyocyte Injury by Inhibition of Inflammatory Responses and Oxidative Stress. 2019 , 2019, 6372786	9
498	Cardiomyopathie du diabétique, diabète et physiologie. 2019 , 11, S30-S45	
497	Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases. 2019 , 20,	8
496	Diabetes and Cardiovascular Disease: an Update. 2019 , 19, 161	20
495	Association of left ventricular myocardial dysfunction with diabetic polyneuropathy. 2019 , 46, 69-79	3
494	Lanosteryl triterpenes from <i>Protorhus longifolia</i> as a cardioprotective agent: a mini review. 2019 , 24, 155-166	4
493	Effects of resveratrol on regulation on UCP2 and cardiac function in diabetic rats. 2019 , 75, 39-51	19
492	Streptozotocin-induced type II diabetic rat administered with nonobesogenic high-fat diet is highly susceptible to myocardial ischemia-reperfusion injury: An insight into the function of mitochondria. 2019 , 234, 4104-4114	9
491	Cardiac Injury, Maladaptation, and Heart Failure Incidence. 2019 , 81-96	1
490	Heart Failure in Type 2 Diabetes Mellitus. 2019 , 124, 121-141	210
489	Right ventricular dysfunction and remodeling in diabetic cardiomyopathy. 2019 , 316, H113-H122	13

488	Of mice and men: models and mechanisms of diabetic cardiomyopathy. 2018 , 114, 2	87
487	Fibrotic Signaling in Cardiomyopathies. 2019 , 273-317	1
486	Apport des modèles murins à la physiopathologie des cardiomyopathies diabétiques. 2019 , 2019, 24-27	
485	MiR-30c/PGC-1 β protects against diabetic cardiomyopathy via PPAR γ . 2019 , 18, 7	43
484	Diabetic cardiomyopathy. 2019 , 105, 337-345	37
483	Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy. 2019 , 24, 279-299	71
482	Proteasome biology and therapeutics in cardiac diseases. 2019 , 205, 64-76	14
481	The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. 2019 , 40, 1671-1677	15
480	Curcumin augments the cardioprotective effect of metformin in an experimental model of type I diabetes mellitus; Impact of Nrf2/HO-1 and JAK/STAT pathways. 2019 , 109, 2136-2144	29
479	Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease. 2019 , 1865, 831-843	37
478	Mitochondrial NAD/NADH Redox State and Diabetic Cardiomyopathy. 2019 , 30, 375-398	50
477	Analysis of ventricular synchrony: A complex puzzle. 2019 , 26, 1659-1666	1
476	Left ventricular mechanical dyssynchrony assessment in long-standing type II diabetes mellitus patients with normal gated SPECT-MPI. 2019 , 26, 1650-1658	6
475	Prognostic value of left ventricular mechanical dyssynchrony indices in long-standing type II diabetes mellitus with normal perfusion and left ventricular systolic functions on SPECT-MPI. 2020 , 27, 1640-1648	4
474	Cardiomyopathy in obesity, insulin resistance and diabetes. 2020 , 598, 2977-2993	52
473	Mitochondrial dysfunction plays a key role in the abrogation of cardioprotection by sodium hydrosulfide post-conditioning in diabetic cardiomyopathy rat heart. 2020 , 393, 339-348	4
472	The metabolic syndrome in heart failure: insights to specific mechanisms. 2020 , 25, 1-7	12
471	Mechanism of Hydrogen Sulfide Preconditioning-Associated Protection Against Ischemia-Reperfusion Injury Differs in Diabetic Heart That Develops Myopathy. 2020 , 20, 155-167	7

470	Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p. 2020 , 69, 34-44	13
469	SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. 2020 , 34, 173-188	4
468	Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications. 2020 , 21, 887-895	12
467	Diabetes Mellitus Is an Independent Predictor for the Development of Heart Failure: A Population Study. 2020 , 95, 124-133	11
466	Altered mitochondrial metabolism in the insulin-resistant heart. 2020 , 228, e13430	35
465	Myocardial Function Assessed by Multi-Layered Two-Dimensional Speckle Tracking Analysis in Asymptomatic Young Subjects with Diabetes Mellitus Type 1. 2020 , 145, 80-87	1
464	Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials. 2019 , 17,	3
463	Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress. 2020 , 78, 153319	16
462	Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy. 2020 , 11, 570421	8
461	Biochemistry of Cardiovascular Dysfunction in Obesity. 2020 ,	1
460	Palmitate-induced toxicity is associated with impaired mitochondrial respiration and accelerated oxidative stress in cultured cardiomyocytes: The critical role of coenzyme Q. 2020 , 68, 104948	3
459	Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucentric to a Holistic View on Patient Management. 2020 , 43, 2001-2009	7
458	The role of insulin resistance in the relation of visceral, abdominal subcutaneous and total body fat to cardiovascular function. 2020 , 30, 2230-2241	2
457	Examining the Relationship and Prognostic Implication of Diabetic Status and Extracellular Matrix Expansion by Cardiac Magnetic Resonance. 2020 , 13, e011000	8
456	Pattern recognition receptor-mediated inflammation in diabetic vascular complications. 2020 , 40, 2466-2484	18
455	Myocardial glucotoxicity: Mechanisms and potential therapeutic targets. 2020 , 113, 736-748	6
454	Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study. 2020 , 19, 197	3
453	Reduced fatty acid uptake aggravates cardiac contractile dysfunction in streptozotocin-induced diabetic cardiomyopathy. 2020 , 10, 20809	4

452	Diabetes and COVID-19 risk: an miRNA perspective. 2020 , 319, H604-H609	9
451	Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). 2020 , 9,	7
450	Systolic dysfunction in asymptomatic type 2 diabetic patients, a harbinger of microvascular complications: A cross-sectional study from North India. 2020 , 17, 1479164120944134	3
449	Curcumin protects cardiomyopathy damage through inhibiting the production of reactive oxygen species in type 2 diabetic mice. 2020 , 530, 15-21	8
448	Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis. 2020 , 15, e0235640	4
447	Identification of potential biomarkers for predicting the early onset of diabetic cardiomyopathy in a mouse model. 2020 , 10, 12352	4
446	Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape. 2020 , 888, 173376	11
445	Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis. 2020 , 19, 177	1
444	Rat pancreatectomy combined with isoprenaline or uninephrectomy as models of diabetic cardiomyopathy or nephropathy. 2020 , 10, 16130	1
443	Mitochondrial Dysfunction in Diabetic Cardiomyopathy: The Possible Therapeutic Roles of Phenolic Acids. 2020 , 21,	16
442	The many-faced hurdle of cardiac involvement in diabetes: where to focus?. 2020 , 11, 2042018820970446	
441	The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy. 2020 , 11, 603247	4
440	Effect and Mechanism of Spores on Alleviation of Diabetic Cardiomyopathy in a Pilot in vivo Study. 2020 , 13, 4809-4822	4
439	Cellular Protein Quality Control in Diabetic Cardiomyopathy: From Bench to Bedside. 2020 , 7, 585309	5
438	SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy. 2020 , 14, 4775-4788	10
437	Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway. 2020 , 261, 118306	5
436	Diabetic cardiomyopathy.. 2022 , 222, 100-111	0
435	Key factors of diastolic dysfunction and abnormal left ventricular relaxation in diabetic rats. 2020 , 47, 347-356	5

434	Sex-specific pattern of left ventricular hypertrophy and diastolic function in patients with type 2 diabetes mellitus. 2021 , 22, 930-940	2
433	The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. 2020 , 2020, 5732956	79
432	Reduced Myocardial Perfusion Reserve in Type 2 Diabetes Is Caused by Increased Perfusion at Rest and Decreased Maximal Perfusion During Stress. 2020 , 43, 1285-1292	10
431	Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway. 2020 , 11, 425	16
430	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. 2020 , 6, 394-404	7
429	Basic Mechanisms of Diabetic Heart Disease. 2020 , 126, 1501-1525	89
428	Sex Differences in Progression of Diabetic Cardiomyopathy in OVE26 Type 1 Diabetic Mice. 2020 , 2020, 6961348	3
427	Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy. 2020 , 19, 84	8
426	The role of diabetes in cardiomyopathies of different etiologies-Characteristics and 1-year follow-up results of the EVITA-HF registry. 2020 , 15, e0234260	1
425	SIRT1 Activation by L. (Horsetail) Modulates Insulin Sensitivity in Streptozotocin Induced Diabetic Rats. 2020 , 25,	5
424	Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation () Mice. 2020 , 11, 769	4
423	Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. 2020 , 75, 1249-1262	25
422	Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes. 2020 , 11, 124	13
421	Resveratrol and Diabetic Cardiomyopathy: Focusing on the Protective Signaling Mechanisms. 2020 , 2020, 7051845	8
420	Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms. 2020 , 8,	10
419	Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis. 2020 , 9,	9
418	Knockout of farnesoid X receptor aggravates process of diabetic cardiomyopathy. 2020 , 161, 108033	2
417	Adeno-Associated Viral Transfer of Glyoxalase-1 Blunts Carbonyl and Oxidative Stresses in Hearts of Type 1 Diabetic Rats. 2020 , 9,	5

416	Diabetes and Heart Failure: A Marriage of Inconvenience. 2020 , 36, 447-455	2
415	Reduced Exercise Capacity in Diabetes Mellitus Is Not Associated with Impaired Deformation or Twist. 2020 , 33, 481-489	4
414	The Peroxisome Proliferator-Activated Receptor-Gamma Coactivator-1 β Heme Oxygenase 1 Axis, a Powerful Antioxidative Pathway with Potential to Attenuate Diabetic Cardiomyopathy. 2020 , 32, 1273-1290	6
413	Curcumin analog A13 alleviates oxidative stress by activating Nrf2/ARE pathway and ameliorates fibrosis in the myocardium of high-fat-diet and streptozotocin-induced diabetic rats. 2020 , 12, 1	40
412	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. 2020 , 17, 585-607	139
411	Diabetic cardiomyopathy. 2020 ,	3
410	Fermented rooibos extract attenuates hyperglycemia-induced myocardial oxidative damage by improving mitochondrial energetics and intracellular antioxidant capacity. 2020 , 131, 143-150	8
409	Diabetic animal fed with high-fat diet prevents the protective effect of myocardial ischemic preconditioning effect in isolated rat heart perfusion model. 2020 , 34, e22457	3
408	The Diabetic Cardiac Fibroblast: Mechanisms Underlying Phenotype and Function. 2020 , 21,	14
407	Diabetes induces differences in the F-actin spatial organization of striated muscles. 2020 , 77, 202-213	4
406	Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM. 2020 , 127, 110081	15
405	Exogenous spermine attenuates rat diabetic cardiomyopathy via suppressing ROS-p53 mediated downregulation of calcium-sensitive receptor. 2020 , 32, 101514	15
404	Diabetic Cardiomyopathy and Ischemic Heart Disease: Prevention and Therapy by Exercise and Conditioning. 2020 , 21,	20
403	Systemic Delivery of siRNA Specific for Silencing TLR4 Gene Expression Reduces Diabetic Cardiomyopathy in a Mouse Model of Streptozotocin-Induced Type 1 Diabetes. 2020 , 11, 1161-1173	8
402	Galectin-3 mediates high-glucose-induced cardiomyocyte injury by the NADPH oxidase/reactive oxygen species pathway. 2020 , 98, 826-833	3
401	Diabetic cardiomyopathy: How can cardiac magnetic resonance help?. 2020 , 57, 1027-1034	9
400	1,25-Dihydroxyvitamin D attenuates diabetic cardiac autophagy and damage by vitamin D receptor-mediated suppression of FoxO1 translocation. 2020 , 80, 108380	11
399	Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses. 2020 , 10, 6427	10

- 398 Incidence of heart failure among diabetic patients with ischemic heart disease: a cohort study. **2020**, 20, 181 1
- 397 Acute Effects of Insulin on Cardiac Function in Patients with Diabetes Mellitus: Clinical Applicability and Feasibility. **2020**, 2020, 8134548
- 396 NOD Mice Recapitulate the Cardiac Disturbances Observed in Type 1 Diabetes. **2021**, 14, 271-282 2
- 395 Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. **2021**, 12, 6-20 7
- 394 Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future. **2021**, 26, 953-960 1
- 393 Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. **2021**, 44, 745-753 2
- 392 MALDI-IMS as a Tool to Determine the Myocardial Response to Syndecan-2-Selected Mesenchymal Stromal Cell Application in an Experimental Model of Diabetic Cardiomyopathy. **2021**, 15, e2000050 1
- 391 Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy. **2021**, 42, 932-941 6
- 390 Mitochondrial calcium handling and heart disease in diabetes mellitus. **2021**, 1867, 165984 8
- 389 How Diabetes and Heart Failure Modulate Each Other and Condition Management. **2021**, 37, 595-608 7
- 388 Elabela may regulate SIRT3-mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic-induced myocardial injury. **2021**, 25, 323-332 12
- 387 Morphological characteristics in diabetic cardiomyopathy associated with autophagy. **2021**, 77, 30-40 4
- 386 Effect of adenosine monophosphate-activated protein kinase-p53-Krüppel-like factor 2a pathway in hyperglycemia-induced cardiac remodeling in adult zebrafish. **2021**, 12, 320-333 4
- 385 Spermine Protects Cardiomyocytes from High Glucose-Induced Energy Disturbance by Targeting the CaSR-gp78-Ubiquitin Proteasome System. **2021**, 35, 73-85 5
- 384 Pericytes in Myocardial Diseases. **2021**, 219-243
- 383 The Effects of Ginsenoside Rb1 on Cardiac Structure, Function and Myocardial Fibrosis in Diabetes Rats. **2021**, 11, 497-504
- 382 Water-soluble lectin (WSMoL) from Moringa oleifera seeds treatment recovers glycemic levels and improves left ventricular ejection fraction on Type-2 Diabetes mice model. **2021**, 93, e20201596 1
- 381 Diabetes Mellitus. **2021**, 375-390

380	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. 2020 , 11, 612722	2
379	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. 2021 , 8, 1130-1138	8
378	Total flavonoids extracted from the leaves of <i>Murraya paniculata</i> (L.) Jack alleviate oxidative stress, inflammation and apoptosis in a rat model of diabetic cardiomyopathy. 2021 , 76, 104319	3
377	Diabetes-induced changes in cardiac voltage-gated ion channels. 2021 , 12, 1-18	7
376	Diabetes and Heart Failure. 2021 , 3, 21	
375	Endothelial Cell Metabolic Memory Causes Cardiovascular Dysfunction In Diabetes. 2021 ,	5
374	Calcium Dobesilate (CaD) Attenuates High Glucose and High Lipid-Induced Impairment of Sarcoplasmic Reticulum Calcium Handling in Cardiomyocytes. 2021 , 8, 637021	
373	Evidence for human diabetic cardiomyopathy. 2021 , 58, 983-988	5
372	BH4 Increases nNOS Activity and Preserves Left Ventricular Function in Diabetes. 2021 , 128, 585-601	4
371	Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. 2021 , 23, 1431-1435	4
370	A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice. 2021 , 10,	1
369	Diabetes and Heart Failure. 2021 , 22, 12-20	
368	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. 2021 ,	4
367	Dysregulation of circulating miRNAs promotes the pathogenesis of diabetes-induced cardiomyopathy. 2021 , 16, e0250773	2
366	Long Non-coding RNA: A Key Regulator in the Pathogenesis of Diabetic Cardiomyopathy. 2021 , 8, 655598	2
365	Apelin/APJ relieve diabetic cardiomyopathy by reducing microvascular dysfunction. 2021 , 249, 1-18	3
364	Heart Failure and Diabetes: Perspective of a Dangerous Association. 2021 , 17, 85-93	1
363	The Acute Effects of Different Spironolactone Doses on Oxidative Stress in Streptozotocin-Induced Diabetic Rats. 2021 ,	

362	Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice. 2021 , 8, 632728	0
361	The triterpene, methyl-3 β -hydroxylanosta-9,24-dien-21-oate (RA3), attenuates high glucose-induced oxidative damage and apoptosis by improving energy metabolism. 2021 , 85, 153546	0
360	Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus. 2021 , 18, 14791641211021585	
359	The role of mitochondria in metabolic disease: a special emphasis on heart dysfunction. 2021 , 599, 3477-3493	4
358	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. 2021 , 22,	16
357	The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy. 2021 , 167, 66-80	5
356	The role of metabolism in directed differentiation versus trans-differentiation of cardiomyocytes. 2021 , 122, 56-56	1
355	Run for your life: can exercise be used to effectively target GLUT4 in diabetic cardiac disease?. 2021 , 9, e11485	2
354	Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis. 2021 , 172, 234-248	2
353	The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis. 2021 , 22,	7
352	Early left ventricular systolic dysfunction in asymptomatic patients with type 1 diabetes: a single-center, pilot study. 2021 , 35, 107913	1
351	Role of novel biomarkers in diabetic cardiomyopathy. 2021 , 12, 685-705	4
350	The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms. 2021 , 8, 695792	16
349	Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. 2021 , 169, 317-342	16
348	Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity. 2021 , 12, 624	16
347	Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives. 2021 , 135, 1369-1387	2
346	Diastolic dysfunction in a pre-clinical model of diabetes is associated with changes in the cardiac non-myocyte cellular composition. 2021 , 20, 116	3
345	Cyanocobalamin prevents cardiomyopathy in type 1 diabetes by modulating oxidative stress and DNMT-SOCS1/3-IGF-1 signaling. 2021 , 4, 775	1

344	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. 2021 , 22,	6
343	CircRNAs in diabetic cardiomyopathy. 2021 , 517, 127-132	3
342	Endogenous asymmetric dimethylarginine accumulation precipitates the cardiac and mitochondrial dysfunctions in type 1 diabetic rats. 2021 , 902, 174081	1
341	Hyperglycemia and hyperlipidemia can induce morphophysiological changes in rat cardiac cell line. 2021 , 26, 100983	0
340	Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus. 2021 , e3484	0
339	Role of Autophagy in Granulocyte-Colony Stimulating Factor Induced Anti-Apoptotic Effects in Diabetic Cardiomyopathy. 2021 , 45, 594-605	1
338	Mitochondrial Arrest on the Microtubule Highway-A Feature of Heart Failure and Diabetic Cardiomyopathy?. 2021 , 8, 689101	3
337	Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes. 2021 , 12, 687256	6
336	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. 2021 , 12, 701275	2
335	Echocardiographic evaluation of the effect of poor blood glucose control on left ventricular function and ascending aorta elasticity. 2021 , 35, 107943	1
334	Advanced Glycation End Products: New Clinical and Molecular Perspectives. 2021 , 18,	2
333	Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy. 2021 , 8, 703355	1
332	Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy.. 2022 , 12, 1-17	2
331	Ultrasound-assisted CF-filled PLGA nanobubbles for enhanced FGF21 delivery and improved prophylactic treatment of diabetic cardiomyopathy. 2021 , 130, 395-408	1
330	KLF15 negatively regulates cardiac fibrosis by which SDF-1 β attenuates cardiac fibrosis in type 2 diabetic mice. 2021 , 427, 115654	2
329	Why the diabetic heart is energy inefficient: a ketogenesis and ketolysis perspective. 2021 , 321, H751-H755	2
328	S-Propargyl-Cysteine Attenuates Diabetic Cardiomyopathy in Mice Through Activation of Cardiac Insulin Receptor Signaling. 2021 , 8, 737191	2
327	Characterisation of the Myocardial Mitochondria Structural and Functional Phenotype in a Murine Model of Diabetic Cardiomyopathy. 2021 , 12, 672252	1

326	Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. 2021 , 176, 113904	5
325	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. 2021 , 21, 41	0
324	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. 2021 , 8, 746382	3
323	Cathelicidin-WA ameliorates diabetic cardiomyopathy by inhibiting the NLRP3 inflammasome. 2021 , 20, 2278-2290	2
322	The Saga of Endocrine FGFs. 2021 , 10,	6
321	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. 2021 , 19, 487-498	1
320	Weighted Gene Co-Expression Network Analysis Identifies ANGPTL4 as a Key Regulator in Diabetic Cardiomyopathy FAK/SIRT3/ROS Pathway in Cardiomyocyte. 2021 , 12, 705154	1
319	Targeting the microRNAs in exosome: A potential therapeutic strategy for alleviation of diabetes-related cardiovascular complication. 2021 , 173, 105868	0
318	Role of high-density lipoproteins in cardioprotection and in reverse remodeling: Therapeutic implications. 2021 , 1866, 159022	1
317	FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin α_5 /FAK signaling and reduction of oxidative/nitrosative stress. 2021 , 160, 27-41	6
316	Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. 2021 , 228, 107920	4
315	Detection of subclinical heart failure. 2022 , 20-50	0
314	Asymptomatic type 2 diabetes mellitus display a reduced myocardial deformation but adequate response during exercise. 2021 , 121, 929-940	1
313	Mst1 Knockout Alleviates Mitochondrial Fission and Mitigates Left Ventricular Remodeling in the Development of Diabetic Cardiomyopathy. 2020 , 8, 628842	4
312	The MEK inhibitor U0126 ameliorates diabetic cardiomyopathy by restricting XBP1's phosphorylation dependent SUMOylation. 2021 , 17, 2984-2999	4
311	PET Measurement of Myocardial Metabolism. 2007 , 227-249	2
310	Diseases associated with altered ryanodine receptor activity. 2007 , 45, 273-321	32
309	Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. 2003 , 113-123	6

308	Autonomic Neuropathy and Heart Disease. 1998 , 209-226	1
307	Hormonal Effects On Cardiac Performance. 1989 , 643-653	1
306	Clinical Manifestations of Diabetic Cardiomyopathy. 1996 , 1-22	1
305	Fatty Acid Metabolism in the Heart Following Diabetes. 1996 , 215-251	3
304	Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. 1996 , 283-288	5
303	The Cardiomyopathies. 1994 , 196-222	3
302	Metabolic Alterations in Diabetic Cardiomyopathy. 2014 , 3-25	1
301	MicroRNomics of Diabetic Cardiomyopathy. 2014 , 179-187	1
300	A Critical Balance Between Oxidative Stress and Antioxidant Defense in Cardiovascular System Under Hyperglycemia: A Summary of Experimental Studies. 2014 , 123-141	1
299	Effect of diabetes mellitus on hemodynamic and cardiometabolic correlates in experimental myocardial infarction. 2001 , 498, 229-40	2
298	Diastolic Disturbances in Diabetes Mellitus. 2008 , 271-284	2
297	Role of Sodium-Glucose Co-transporters on Cardiac Function in Metabolic Syndrome Mammalians. 2020 , 125-144	1
296	Therapeutic potential of HDL in cardioprotection and tissue repair. 2015 , 224, 527-65	31
295	Impact of Endocrine Disorders on the Heart. 2019 , 1-37	1
294	Role of Non-coding RNA in Diabetic Cardiomyopathy. 2020 , 1229, 181-195	9
293	Consensus document: management of heart failure in type 2 diabetes mellitus. 2021 , 26, 1037-1062	2
292	Global longitudinal strain as a biomarker in diabetic cardiomyopathy. A comparative study with Gal-3 in patients with preserved ejection fraction. 2017 , 87, 278-285	9
291	Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathy. 2020 , 128, 110260	9

290	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HF _{rEF} : The CHAMP-HF Registry. 2020 , 8, 469-480	16
289	Cardiomyopathie Diabétique: une entité spécifique?. 2017 , 201, 325-337	1
288	Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy. 2020 , 126, 1628-1645	14
287	Engulfment and cell motility protein 1 potentiates diabetic cardiomyopathy via Rac-dependent and Rac-independent ROS production. 2019 , 4,	8
286	Adipocyte-specific loss of PPAR attenuates cardiac hypertrophy. 2016 , 1, e89908	50
285	The cardiac phenotype induced by PPAR β overexpression mimics that caused by diabetes mellitus. 2002 , 109, 121-130	649
284	Evidence for cardiomyopathy in familial diabetes mellitus. 1977 , 60, 884-99	538
283	Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue. 1995 , 96, 1759-67	49
282	The cardiac phenotype induced by PPAR α overexpression mimics that caused by diabetes mellitus. 2002 , 109, 121-30	364
281	Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics. 2020 , 19, 158	7
280	Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction - Novel Prospective Cohort Study. 2019 , 1, 286-295	9
279	Left ventricular diastolic dysfunction in diabetes mellitus and the therapeutic role of exercise training. 2019 , 10, 145-152	2
278	Label-free and noninvasive method for assessing the metabolic status in type 2 diabetic rats with myocardium diastolic dysfunction. 2021 , 12, 480-493	3
277	The critical role of Astragalus polysaccharides for the improvement of PPAR δ correction of PPAR α -mediated lipotoxicity in diabetic cardiomyopathy. 2012 , 7, e45541	25
276	β -blocker timolol prevents arrhythmogenic Ca ²⁺ release and normalizes Ca ²⁺ and Zn ²⁺ dyshomeostasis in hyperglycemic rat heart. 2013 , 8, e71014	38
275	Increased systemic Th17 cytokines are associated with diastolic dysfunction in children and adolescents with diabetic ketoacidosis. 2013 , 8, e71905	15
274	Flos Puerariae extract prevents myocardial apoptosis via attenuation oxidative stress in streptozotocin-induced diabetic mice. 2014 , 9, e98044	21
273	A STUDY TO CORRELATE HBA1C LEVELS AND LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN NEWLY DIAGNOSED TYPE II DIABETES MELLITUS. 2016 , 5, 3312-3317	3

272	Intermittent hypoxia induces beneficial cardiovascular remodeling in left ventricular function of type 1 diabetic rat. 2018 , 19, 259-266	5
271	Cardiac fibrosis and down regulation of GLUT4 in experimental diabetic cardiomyopathy are ameliorated by chronic exposures to intermittent altitude. 2016 , 8, 26-33	15
270	Evolution of subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking in asymptomatic type 1 diabetic patients: a long-term follow-up study. 2017 , 4, 73-81	10
269	Influence of Race in the Association of Diabetes and Heart Failure. 2018 , 12, 17-21	1
268	Protective effects of Macrotyloma uniflorum seeds (horse gram) in abnormalities associated with the metabolic syndrome in rats. 2015 , 2, 1-10	3
267	Chronic heart failure and type 2 diabetes: state of the problem. 2020 , 25, 3858	4
266	[Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]. 2019 , 59, 76-87	6
265	Apocynin attenuates left ventricular remodeling in diabetic rabbits. 2017 , 8, 38482-38490	12
264	Diabetic Cardiomyopathy in OVE26 Mice Shows Mitochondrial ROS Production and Divergence Between In Vivo and In Vitro Contractility. 2007 , 4, 159-68	30
263	Beneficial Effects of Echinacoside on Diabetic Cardiomyopathy in Diabetic Mice. 2020 , 14, 5575-5587	2
262	Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling. 2019 , 26, 4166-4177	3
261	Macrovascular Complications of Type 2 Diabetes Mellitus. 2020 , 18, 110-116	41
260	Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy. 2021 , 22, 268-278	4
259	Editorial: Heart Failure in Type 2 Diabetes [The Forgotten] Complication. 2018 , 25, 123-130	3
258	The effect of diabetes mellitus on the ventricular epicardial activation and repolarization in mice. 2012 , 61, 363-70	5
257	Inflammatory Serine Proteases Play a Critical Role in the Early Pathogenesis of Diabetic Cardiomyopathy. 2019 , 53, 982-998	6
256	Assessment of the Preventive Effect Against Diabetic Cardiomyopathy of FGF1-Loaded Nanoliposomes Combined With Microbubble Cavitation by Ultrasound. 2019 , 10, 1535	6
255	Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials. 2020 , 2, 12	8

254	SIRT3 is a downstream target of PPAR- β implicated in high glucose-induced cardiomyocyte injury in AC16 cells. 2020 , 20, 1261-1268	2
253	Current advances in the study of diabetic cardiomyopathy: From clinicopathological features to molecular therapeutics (Review). 2019 , 20, 2051-2062	5
252	Calcium inhibitor inhibits high glucose-induced hypertrophy of H9C2 cells. 2020 , 22, 1783-1792	4
251	Mitochondrial Mechanisms in Diabetic Cardiomyopathy. 2020 , 44, 33-53	35
250	Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. 2019 , 10, 490-510	34
249	Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. 2015 , 6, 943-60	38
248	Is diabetic cardiomyopathy a specific entity?. 2014 , 6, 8-13	13
247	Mechanisms underlying the impaired contractility of diabetic cardiomyopathy. 2014 , 6, 577-84	31
246	Alpha-lipoic acid and vitamin B complex slow down the changes in mice diabetic cardiomyopathy. 2020 , 61, 521-528	2
245	LEFT VENTRICULAR DIASTOLIC FILLING IN YOUNG PERSONS WITH TYPE 1 DIABETES MELLITUS. 2003 , 147, 57-61	5
244	Increased relative wall thickness is a marker of subclinical cardiac target-organ damage in African diabetic patients. 2012 , 23, 435-41	6
243	Presystolic Wave is Associated with Subclinical Left Ventricular Dysfunction Assessed by Myocardial Performance Index in Type 2 Diabetes Mellitus. 2019 , 113, 207-215	3
242	Necropsy findings in a cat with diabetes mellitus and heart failure. 2021 , 7, 20551169211055383	
241	Hydrogen sulfide plays a potential alternative for the treatment of metabolic disorders of diabetic cardiomyopathy. 2021 , 1	2
240	Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane AMPK/NRF2 pathways.. 2022 , 12, 708-722	11
239	Diabetes With Cardiomyopathy: At the Juncture of Knowledge and Prevention. 2021 , 78, 1599-1602	1
238	The role of hyperglycaemia in the development of diabetic cardiomyopathy. 2021 , 114, 748-760	5
237	Possibilities of predicting preclinical forms of cardiovascular diseases in young patients with type 1 diabetes mellitus using cardiac magnetic resonance imaging. 2021 , 36, 51-58	

- 236 Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes. **2021**, 10, 0
- 235 An Updated Insight Into Molecular Mechanism of Hydrogen Sulfide in Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury Under Diabetes. **2021**, 12, 651884 2
- 234 The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?. **2021**, 108008 1
- 233 MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis. **2021**, 174, 105941 6
- 232 Heart failure in diabetes. **2021**, 125, 154910 15
- 231 Epigenetic Alterations in Diabetic Cardiomyopathy. **2003**, 465-479
- 230 [Clinical and echocardiographic characteristics of patients with diabetic cardiomyopathy]. **2004**, 61, 259-66
- 229 Early Up-Regulation of Multiple Signaling Pathways in Type I Diabetic Cardiomyopathy. **2006**, 6, 812-817
- 228 Echocardiography in the Evaluation of Cardiac Disease Resulting from Endocrinopathies, Renal Disease, Obesity, and Nutritional Deficiencies. **2007**, 902-931
- 227 Diabetes Mellitus and Exercise Physiology in the Presence of Diabetic Comorbidities. **2009**, 163-183
- 226 Diabetic Cardiomyopathy. **2009**, 33, 9
- 225 Congestive Heart Failure. 684-697
- 224 Uncoupling protein 2 regulates myocardial apoptosis via the diabetogenic action of streptozotocin. **2011**, 04, 506-510
- 223 Role of Oxidative Stress and Targeted Antioxidant Therapies in Experimental Models of Diabetic Complications. **2011**, 3-38
- 222 Does impaired glucose tolerance associate with heart failure?. **2012**, 18, 245-251
- 221 Abnormalities in ATP Production and Utilization in Diabetic Cardiomyopathy. **2014**, 299-310
- 220 Nutritional Management of Cardiovascular Complications Caused by Diabetes. **2014**, 397-412
- 219 Role of PPAR- γ in Diabetic Cardiomyopathy. **2014**, 201-212

- 218 Effects of Diabetes-Induced Hyperglycemia in the Heart: Biochemical and Structural Alterations. **2014**, 77-106 1
- 217 ECHOCARDIOGRAPHIC EVALUATION OF DIASTOLIC DYSFUNCTION IN ASYMPTOMATIC TYPE 2 DIABETES MELLITUS PATIENTS. **2014**, 3, 200-209 1
- 216 Small Vessel Disease. **1982**, 231-282 4
- 215 Hormonal Effects on Cardiac Performance. **1984**, 593-603
- 214 Application of Symbolic Logic to the Morphometric Study of Coronary Diabetic Microangiopathy. **1986**, 553-559
- 213 Cardiac Dysfunction in the Diabetic Heart. **1987**, 165-176
- 212 The Heart in Diabetes in Early and Advanced Nephropathy. **1988**, 303-311
- 211 Diabetic Cardiomyopathy with Special Reference to Hypertension. **1988**, 46-51
- 210 Electron Microscopic Cytochemical Studies on ATPase and Acid Phosphatase Activities of Cardiac Myocytes in Streptozotocin Induced Diabetic Rats. **1992**, 211-224
- 209 Early Diastolic Dysfunction of Left Ventricle and its Relation to Pathologic Finding in Patients with Diabetes Mellitus. **1992**, 9-20
- 208 Variables affecting cardiac output in obesity and diabetes. **1992**, 395-407
- 207 Effects of Beta-Adrenoceptor Blocking Agents on Myocardium Isolated from Experimentally Diabetic Rats. **1992**, 283-296
- 206 Radionuclide Assessment of Left Ventricular Function in Middle-Aged Asymptomatic Non-Insulin-Dependent Diabetic Patients. **1992**, 21-33
- 205 Diabetes Prolongs the Action Potential Duration in Rat Ventricular Muscle Probably Via Enhanced Calcium Current. **1992**, 155-171
- 204 Usefulness of Exercise Tl-201 Myocardial Scintigraphy to Detect Asymptomatic Heart Disease in Diabetic Patients. **1992**, 35-45
- 203 Biochemical and Morphologic Alterations in Cardiac Myocytes in Streptozotocin-Induced Diabetic Rats. **1992**, 139-153 1
- 202 The Metabolic Syndrome. **1999**, 221-242
- 201 Contemporary Echocardiographic Techniques in Early Detection of Diabetic Cardiomyopathy. **2014**, 1, 1 1

- 200 Effects of aerobic exercise on antioxidants in rat models with cardiomyopathy. **2015**, 4, 17-21 1
- 199 Coronary Artery Disease and Cardiomyopathy. **2016**, 1-21
- 198 The impact of diabetes on left ventricular diastolic function in patients with arterial hypertension. **2015**, 2, 177-181 4
- 197 New peroral antidiabetic drugs and heart failure. **2016**, 18, 78-82
- 196 Subclinical Left Ventricular Dysfunction in Asymptomatic Type 1 Diabetic Children. **2016**, 6,
- 195 Coronary Artery Disease and Cardiomyopathy. **2017**, 1-21
- 194 Coronary Artery Disease and Cardiomyopathy. **2017**, 637-657
- 193 Heart Failure Prevention. **2017**, 267-284 2
- 192 Protease Cathepsins in Cardiomyopathy: From Mechanism to Intervention. **2017**, 447-462
- 191 DIABETES AND HEART FAILURE. **2017**, 6, 2852-2855
- 190 Diyabetik Kardiyomiyopati Sın Modelinde Oksitosin Etkilerinin Histolojik ve Biyokimyasal Olarak İncelenmesi. **2017**, 44, 135-135 0
- 189 Assessment of left ventricular functions in patients with type 2 diabetes mellitus using tissue Doppler imaging and its correlation with a novel cardiac biomarker. **2017**, 29, 181-188
- 188 Oxidative Stress and Labile Zinc in Heart Dysfunction Under Hyperglycemia. **2019**, 397-412
- 187 Diabetes and Cardiovascular Disease. **2019**, 709-730
- 186 Histone Deacetylases and Oxidative Stress: Role in Diabetic Cardiomyopathy. **2019**, 413-425 3
- 185 Regulating Inflammatory Cytokines in the Diabetic Heart. **2019**, 427-436
- 184 Diabetic Cardiomyopathy: Five Major Questions with Simple Answers. **2019**, 13, 46-48
- 183 Heart failure and diabetes mellitus: insight into comorbidity. **2019**, 22, 79-87 1

- 182 Diabetes Mellitus and Chronic Heart Failure. **2019**, 65, 307-313
- 181 Predictors of early cardiac changes in patients with type 1 diabetes mellitus: An echocardiography-based study. **2019**, 19, 384-391 0
- 180 Diabetic Cardiomyopathy: Present Status and Future Directions. **2019**, 225-235
- 179 Preoperative echocardiographic evaluation of cardiac systolic and diastolic function in liver transplant recipients with diabetes mellitus: a propensity-score matched analysis. **2019**, 14, 465-473
- 178 A modern view on the mechanisms of diabetic cardiomyopathy development and the its modification options. **2019**, 142-147 1
- 177 Cardiovascular remodeling in patients with diabetic cardiomyopathy. **2019**, 42-47 2
- 176 Palmitate-induced toxicity is associated with impaired mitochondrial respiration and accelerated oxidative stress in cultured cardiomyocytes: the critical role of Coenzyme Q9/10.
- 175 Echocardiographic Diagnosis of Diabetic Cardiomyopathy. **2020**, 5, 17-23
- 174 Therapeutic Approach of Flavonoid in Ameliorating Diabetic Cardiomyopathy by Targeting Mitochondrial-Induced Oxidative Stress. **2021**, 22, 3
- 173 Review of Insulin Resistance in Dilated Cardiomyopathy and Implications for the Pediatric Patient Short Title: Insulin Resistance DCM and Pediatrics. **2021**, 9, 756593 0
- 172 Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. **2021**, 1 1
- 171 A pathomorphological study on the diabetogenic drug-induced heart disease in the rat. **1983**, 70-77
- 170 The Effect of High Intensity Aerobic Exercise on Levels of Galectin-3 and Protein Kinase C in Diabetic Male Rats. **2020**, 9,
- 169 Assessment of real-time three-dimensional echocardiography as a tool for evaluating left atrial volume and function in patients with type 2 diabetes mellitus. **2020**, 13, 991-1000 0
- 168 Heart Failure in Diabetes Mellitus: An Updated Review. **2020**, 26, 5933-5952 1
- 167 Incidence of Heart Failure among Diabetic Patients with Ischemic Heart Disease: A Cohort Study.
- 166 Incidence of Heart Failure among Diabetic Patients with Ischemic Heart Disease: A Cohort Study.
- 165 De la diabetes a la insuficiencia cardiaca ¿Existe la miocardiopatía diabética?. **2020**, 27, 12-16

164	Cardiomyopathy in Saudi Arabia: The King Khalid University Hospital Experience. 1988 , 8, 452-456	1
163	Diabetische Herzmuskelerkrankung. 2005 , 157-173	
162	Cardiac PET Imaging: Current Status and Limitations. 2009 , 387-399	
161	Mechanisms of Diabetes Mellitus-Induced Sudden Cardiac Death.	
160	Diabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failure. 2020 , 1, 93-101	
159	Impact of Endocrine Disorders on the Heart. 2021 , 59-95	
158	Diabetic cardiomyopathy: is resistin a culprit?. 2015 , 5, 387-93	6
157	The heart in diabetes. 1984 , 140, 583-93	11
156	Cardiomyopathy in diabetic patients. 1984 , 140, 610-2	1
155	Hypertensive-diabetic cardiomyopathy in the rat: an experimental model of human disease. 1981 , 102, 219-28	104
154	Cardiovascular disorders in patients with diabetes mellitus. 2006 , 11, 237-8	1
153	A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. 2007 , 3, 967-73	33
152	Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway. 2015 , 8, 466-73	21
151	Upregulation of arginase activity contributes to intracellular ROS production induced by high glucose in H9c2 cells. 2015 , 8, 2728-36	14
150	Exogenous spermine ameliorates high glucose-induced cardiomyocytic apoptosis via decreasing reactive oxygen species accumulation through inhibiting p38/JNK and JAK2 pathways. 2015 , 8, 15537-49	12
149	Phasic change and apoptosis regulation of JAK2/STAT3 pathway in a type 2 diabetic rat model. 2019 , 11, 911-930	6
148	MiR-144 affects proliferation and apoptosis of high glucose-induced AC16 cardiomyocytes by regulating CTRP3/JNK signaling. 2020 , 13, 142-152	4
147	Mitochondrial shaping proteins as novel treatment targets for cardiomyopathies. 2020 , 3, 216-226	2

146	Exercise alleviates cardiac remodelling in diabetic cardiomyopathy via the miR-486a-5p-Mst1 pathway. 2021 , 24, 150-159	1
145	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. 2020 , 3, 82-97	2
144	Activation of Silent Information Regulator 6 Signaling Attenuates Myocardial Fibrosis by Reducing TGF β 1-Smad2/3 Signaling in a Type 2 Diabetic Animal Model. 2021 , Publish Ahead of Print,	
143	SIRT1-FOXOs activity regulates diabetic complications. 2021 , 175, 106014	2
142	Impact of diabetes on cardiopulmonary function: the added value of a combined cardiopulmonary and echocardiography stress test. 2021 , 1	5
141	The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity. 2021 , 10,	3
140	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. 2021 , 1	3
139	Cardiac Regenerative Therapy in Diabetes: Challenges and Potential Therapeutics. 2021 , 71-79	
138	Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.. 2022 , 1	4
137	Transforming growth factor- β in myocardial disease.. 2022 ,	11
136	Exosomal microRNAs: potential targets for the prevention and treatment of diabetic cardiomyopathy.. 2022 ,	1
135	Amylin. 2022 , Publish Ahead of Print,	0
134	Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy.. 2022 , 2022, 5913374	4
133	SGLT2 Inhibitors and Their Antiarrhythmic Properties.. 2022 , 23,	0
132	Ca mishandling and mitochondrial dysfunction: a converging road to prediabetic and diabetic cardiomyopathy.. 2022 , 474, 33	1
131	Ranolazine Inhibits Pyroptosis Regulation of miR-135b in the Treatment of Diabetic Cardiac Fibrosis.. 2022 , 9, 806966	1
130	Molecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy.. 2021 , 8, 725532	0
129	Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. 2003 , 249, 113-23	16

128	Role of inflammation in diabetic cardiomyopathy.. 2022 , 13, 20420188221083530	2
127	Biomarkers of Myocardial Fibrosis in Diabetes, Echocardiography, and Magnetic Resonance Imaging. 2022 , 1-28	
126	Automatic Microaneurysms Detection for Early Diagnosis of Diabetic Retinopathy Using Improved Discrete Particle Swarm Optimization.. 2022 , 12,	2
125	Growing role of SGLT2i in heart failure: evidence from clinical trials.. 2022 ,	2
124	2-Arachidonoylglycerol Attenuates Myocardial Fibrosis in Diabetic Mice Via the TGF- β 1/Smad Pathway.. 2022 , 1	0
123	The multifaceted role of cytochrome P450-Derived arachidonic acid metabolites in diabetes and diabetic cardiomyopathy.. 2022 , 1-20	0
122	Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy Inhibition of TGF- β /Smad Pathway.. 2022 , 13, 850542	1
121	Proteomic Analysis Suggests Altered Mitochondrial Metabolic Profile Associated With Diabetic Cardiomyopathy.. 2022 , 9, 791700	2
120	Downregulation of secreted frizzled-related protein 4 inhibits hypoxia/reoxygenation injury in diabetic cardiomyocytes by protein tyrosine phosphatase nonreceptor type 12.. 2022 , 13, 7697-7708	
119	Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults.. 2022 , e022308	1
118	Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy.. 2022 , 13, 842313	0
117	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.. 2022 , 23,	3
116	Diabetes and Myocardial Fibrosis: Is CMR the Force Leading to the Rise of "Scar Wars"?. 2022 , 15, 809-811	0
115	Changes in microRNA expression profiles in diabetic cardiomyopathy rats following H3 relaxin treatment.. 2021 , 79,	
114	Cardioprotective effect of extracellular vesicles derived from ticagrelor-pretreated cardiomyocyte on hyperglycemic cardiomyocytes through alleviation of oxidative and endoplasmic reticulum stress.. 2022 , 12, 5651	0
113	Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: a nationwide cohort study.. 2022 , 109838	0
112	Regulating Polyamine Metabolism by miRNAs in Diabetic Cardiomyopathy.. 2021 , 21, 52	0
111	Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes.. 2021 , 9, 777258	1

110	Role of Diabetes Mellitus in Acute Coronary Syndrome Patients with Heart Failure and Midrange Ejection Fraction Who Have Undergone Percutaneous Coronary Intervention: A 3-Year Case-Series Follow-Up Retrospective Study.. 2021 , 14, 4931-4944	0
109	Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment.. 2021 ,	0
108	Role of Oxidative Stress in Diabetic Cardiomyopathy.. 2022 , 11,	5
107	Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis.. 2022 , 9, 865489	1
106	Pharmacological blockade of angiotensin II receptor restores diabetes-associated reduction of store operated Ca entry in adult cardiomyocytes.. 2022 , 610, 56-60	1
105	Image_1.JPEG. 2020 ,	
104	Image_2.JPEG. 2020 ,	
103	Image_3.JPEG. 2020 ,	
102	Presentation_1.PPTX. 2020 ,	
101	Table_1.docx. 2018 ,	
100	Image_1.tif. 2018 ,	
99	Table_1.DOC. 2018 ,	
98	Table_2.DOC. 2018 ,	
97	Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis.. 2022 , 1	1
96	Glycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study.. 2022 , 22, 186	0
95	Editorial: Translational Approaches for Targeting Cardiovascular Complications of Diabetes. 2021 , 12, 799020	
94	Ketogenic Diet and Cardiac Substrate Metabolism.. 2022 , 14,	1
93	Plin5, a New Target in Diabetic Cardiomyopathy.. 2022 , 2022, 2122856	1

- 92 ERK/RSK-mediated phosphorylation of Y-box binding protein-1 aggravates diabetic cardiomyopathy by suppressing its interaction with deubiquitinase OTUB1.. **2022**, 101989 1
- 91 Metabonomic Characteristics of Myocardial Diastolic Dysfunction in Type 2 Diabetic Cardiomyopathy Patients. **2022**, 13, 1
- 90 Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy. **2022**, 13, 387-407
- 89 Capsaicin Alleviates Vascular Endothelial Dysfunction and Cardiomyopathy via TRPV1/eNOS Pathway in Diabetic Rats. **2022**, 2022, 1-11 0
- 88 Diastolic Function. **2016**, 173-197
- 87 Duration of Diabetes, Glycemic Control and Risk of Heart Failure Among Adults with Diabetes: A Cohort Study.
- 86 Biochemical mechanism underlying the pathogenesis of diabetic retinopathy and other diabetic complications in humans: the methanol-formaldehyde-formic acid hypothesis. **2022**, 54, 415-451
- 85 Increased cardiac Pi/PCr in the diabetic heart observed using phosphorus magnetic resonance spectroscopy at 7T. **2022**, 17, e0269957 0
- 84 The Role of Mitochondria in Metabolic SyndromeAssociated Cardiomyopathy. **2022**, 2022, 1-17 0
- 83 Oxidative stress in metabolic diseases: current scenario and therapeutic relevance. 0
- 82 Chronic Hyperglycaemia Inhibits Tricarboxylic Acid Cycle in Rat Cardiomyoblasts Overexpressing Glucose Transporter Type 4. **2022**, 23, 7255 0
- 81 Investigating microRNAs in diabetic cardiomyopathy as tools for early detection and therapeutics. 0
- 80 Cardiovascular diseases and diabetes mellitus. **2022**, 8, 541-549 0
- 79 Exosomal microRNAs in diabetic heart disease. **2022**, 21, 0
- 78 Alpha-lipoic acid treatment improves adverse cardiac remodelling in the diabetic heart The role of cardiac hydrogen sulfide-synthesizing enzymes. **2022**, 115179 0
- 77 The Diabetic Cardiorenal Nexus. **2022**, 23, 7351 1
- 76 LKB1: An emerging therapeutic target for cardiovascular diseases. **2022**, 120844 0
- 75 Epicardial adipose tissue and right ventricular function in type 2 diabetes mellitus using two-dimensional speckle tracking echocardiography. **2022**, 19, 14791641221186

74	The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function. 2022 , 12, 1113	0
73	Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. 2022 , 11, 180-202	1
72	Knowledge domain and emerging trends in diabetic cardiomyopathy: A scientometric review based on CiteSpace analysis. 9,	1
71	Diabetic cardiomyopathy as a diffuse myocardial disease: Is it just fibrosis?. 2022 , 365, 58-59	
70	Fufang Xueshuantong Improves Diabetic Cardiomyopathy by Regulating the Wnt/ β -Catenin Pathway. 2022 , 2022, 1-10	0
69	NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy. 2022 , 23, 10632	1
68	Diabetes-induced chronic heart failure is due to defects in calcium transporting and regulatory contractile proteins: cellular and molecular evidence.	1
67	Functional components of Chinese rice wine can ameliorate diabetic cardiomyopathy through the modulation of autophagy, apoptosis, gut microbiota, and metabolites. 9,	1
66	Dual-specificity phosphatase 12 attenuates oxidative stress injury and apoptosis in diabetic cardiomyopathy via the ASK1-JNK/p38 signaling pathway. 2022 , 192, 13-24	0
65	Circular RNAs: New Players in Cardiomyopathy. 2022 , 13, 1537	0
64	The need for adjusting experimental models to meet clinical reality.	0
63	Relaxin-3 Ameliorates Diabetic Cardiomyopathy by Inhibiting Endoplasmic Reticulum Stress. 2022 , 2022, 1-7	0
62	Biomarkers of Myocardial Fibrosis in Diabetes, Echocardiography, and Magnetic Resonance Imaging. 2023 , 821-847	0
61	The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.	1
60	Polyphenols target miRNAs as a therapeutic strategy for diabetic complications. 1-17	0
59	Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. 9,	0
58	Exosomes derived from human umbilical cord mesenchymal stem cells (HUCMSC-EXO) regulate autophagy through AMPK-ULK1 signaling pathway to ameliorate diabetic cardiomyopathy. 2022 ,	0
57	Early Diabetic Retinopathy Detection Using Elevated Continuous Particle Swarm Optimization Clustering With Raspberry PI. 2022 , 15-33	0

- 56 Mitochondrial quality control mechanisms as molecular targets in diabetic heart. **2022**, 137, 155313 ○
- 55 Exogenous spermidine alleviates diabetic cardiomyopathy via suppressing Pannexin-1-mediated ferroptosis in db/db mice. ○
- 54 Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. ○
- 53 Myocardial Extracellular Volume Expansion in Type 2 Diabetes Is Associated With Ischemic Heart Disease, Autonomic Neuropathy, and Active Smoking. ○
- 52 Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012–2021): A bibliometric analysis. 9, ○
- 51 Therapeutic overexpression of miR-92a-2-5p ameliorated cardiomyocyte oxidative stress injury in the development of diabetic cardiomyopathy. **2022**, 27, ○
- 50 Proteomic and metabolomic analyses reveal the novel targets of spermine for alleviating diabetic cardiomyopathy in type II diabetic mice. 9, ○
- 49 Augmentation and Evaluation of an Olive Oil Based Polyherbal Combination against Diabetic Cardiomyopathy in Experimental Model of Rodents. **2022**, 3, 561-582 ○
- 48 The importance of caveolin as a target in the prevention and treatment of diabetic cardiomyopathy. 13, ○
- 47 Multi-modality cardiac imaging in the management of diabetic heart disease. 9, ○
- 46 Resveratrol improves diabetic cardiomyopathy by preventing asymmetric dimethylarginine-caused peroxisome proliferator-activated receptor- α coactivator-1 β acetylation. **2022**, 936, 175342 ○
- 45 Duration of Diabetes, Glycemic Control, and Risk of Heart Failure Among Adults With Diabetes: A Cohort Study. ○
- 44 Glucagon-Like Peptide-1 (GLP-1) Rescue Diabetic Cardiac Dysfunctions in Human iPSC-Derived Cardiomyocytes. 2200130 ○
- 43 Metrn1 ameliorates diabetic cardiomyopathy via inactivation of cGAS/STING signaling dependent on LKB1/AMPK/ULK1-mediated autophagy. **2022**, 2 ○
- 42 Diabetic cardiomyopathy: a brief summary on lipid toxicity. 1
- 41 Involvement of circRNAs in the Development of Heart Failure. **2022**, 23, 14129 ○
- 40 PERK/ATF4-dependent expression of the stress response protein REDD1 promotes pro-inflammatory cytokine expression in the heart of obese mice. ○
- 39 Energy substrate metabolism and oxidative stress in metabolic cardiomyopathy. 1

- 38 Inhibition of Toll-like Receptor-4 expression for amelioration of myocardial injury in diabetes: A meta-analysis. **2022**, 77, 100137 ○
- 37 Serum Annexin A2 concentrations are increased in patients with diabetic cardiomyopathy and are linked to cardiac dysfunctions. **2023**, 195, 110196 ○
- 36 Phenotypic Disease Network-Based Multimorbidity Analysis in Idiopathic Cardiomyopathy Patients with Hospital Discharge Records. **2022**, 11, 6965 ○
- 35 Molecular mechanisms and promising role of dihydromyricetin in cardiovascular diseases. **2022**, 71, 749-762 ○
- 34 Therapeutic potential of oxymatrine in impeding the cardiomyopathy in the STZ- nicotinamide induced diabetes through SIRT1/Nrf2 signaling activation. ○
- 33 Microvascular Disease and the Pathogenesis of Heart Failure in Diabetes: A Tiny Piece of the Tricky Puzzle. **2022**, 45, 2817-2819 ○
- 32 Genome Editing and Diabetic Cardiomyopathy. **2023**, 103-114 ○
- 31 Therapeutic potential of oxymatrine in impeding the cardiomyopathy in the STZ- nicotinamide induced diabetes through SIRT1/Nrf2 signaling activation. ○
- 30 The Prognostic Efficacy of DPP4 Inhibitors in Asian HFpEF. **2023**, ○
- 29 Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway. **2023**, 24, 858 1
- 28 Quantitative MRI in cardiometabolic disease: From conventional cardiac and liver tissue mapping techniques to multi-parametric approaches. 9, ○
- 27 Feasibility study of automated cardiac motion quantification to assess left ventricular function in type 2 diabetes. **2023**, 13, ○
- 26 Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 47, 10-26 ○
- 25 Immunopharmacological Activities of Luteolin in Chronic Diseases. **2023**, 24, 2136 ○
- 24 Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 5, 1 2
- 23 Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. **2023**, 11, 662 ○
- 22 Diabetes mellitus and hemodynamics in advanced heart failure. **2023**, 379, 60-65 ○
- 21 Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. **2023**, 1869, 166714 ○

- 20 Pyruvate Dehydrogenase Complex and Glucose Oxidation as a Therapeutic Target in Diabetic Heart Disease. **2023**, 12, 47
- 19 Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. **2023**, 21,
- 18 Inflammation, dysregulated iron metabolism, and cardiovascular disease. 4,
- 17 Myocardin-related transcription factor A, regulated by serum response factor, contributes to diabetic cardiomyopathy in mice. **2023**, 317, 121470
- 16 Impaired calcium handling mechanisms in atrial trabeculae of diabetic patients. **2023**, 11,
- 15 Salvianolic acid A improve mitochondrial respiration and cardiac function via inhibiting apoptosis pathway through CRYAB in diabetic cardiomyopathy. **2023**, 160, 114382
- 14 Systemic proinflammatory and profibrotic response in aortic stenosis patients with diabetes and its relationship with myocardial remodeling and clinical outcome. **2023**, 22,
- 13 Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy. **2023**, 12, 1565
- 12 Influence of Flavonoid-Rich Fraction of *Monodora tenuifolia* Seed Extract on Blood Biochemical Parameters in Streptozotocin-Induced Diabetes Mellitus in Male Wistar Rats. **2023**, 13, 292
- 11 Is non-alcoholic fatty liver disease a sign of left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus? A systematic review and meta-analysis. **2023**, 11, e003198
- 10 Assessment of subclinical left ventricular systolic dysfunction in patients with type 2 diabetes: Relationship with HbA1c and microvascular complications. **2023**, 15, 264-274
- 9 Left ventricular systolic dyssynchrony: a novel imaging marker for early assessment of myocardial damage in Chinese type 2 diabetes mellitus patients with normal left ventricular ejection fraction and normal myocardial perfusion.
- 8 Diabetes Induces Cardiac Fibroblast Activation, Promoting a Matrix-Preserving Nonmyofibroblast Phenotype, Without Stimulating Pericyte to Fibroblast Conversion.
- 7 Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP. Volume 17, 791-806
- 6 Novel model predicts diastolic cardiac dysfunction in type 2 diabetes. **2023**, 55, 766-777
- 5 New Insights into the Role of Ferroptosis in Cardiovascular Diseases. **2023**, 12, 867
- 4 Regulated cell death pathways in cardiomyopathy.
- 3 Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy. 14,

- 2 Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024 ○
- 1 The right ventricular dysfunction and ventricular interdependence in patients with DM: assessment using cardiac MR feature tracking. **2023**, 22, ○